ARTICLES SCIENTIFIQUES SUR LE CANCER DU SEIN

Guidelines for reporting secondary findings of genome sequencing in cancer genes: the SFMPP recommendations.

Pujol P, Vande Perre P, Faivre L, Sanlaville D, Corsini C, Baertschi B, Anahory M, Vaur D, Olschwang S, Soufir N, Bastide N, Amar S, Vintraud M, Ingster O, Richard S, Le Coz P, Spano JP, Caron O, Hammel P, Luporsi E, Toledano A, Rebillard X, Cambon-Thomsen A, Putois O, Rey JM, Hervé C, Zorn C, Baudry K, Galibert V, Gligorov J, Azria D, Bressac-de Paillerets B, Burnichon N, Spielmann M, Zarca D, Coupier I, Cussenot O, Gimenez-Roqueplo AP, Giraud S, Lapointe AS, Niccoli P, Raingeard I, Le Bidan M, Frebourg T, Rafii A, Geneviève

D.Eur J Hum Genet. 2018 Dec;26(12):1732-1742. doi: 10.1038/s41431-018-0224-1. Epub 2018 Aug 8.PMID: 30089825 Free PMC article.

 

Reply: Minimally Invasive Laparoscopically Dissected Deep Inferior Epigastric Artery Perforator Flap: An Anatomical Feasibility Study and a First Clinical Case.

Benjoar MD, Berdah Y, Dubosq F, Zarca D, Lantieri L, Hans S, Hivelin M.

Plast Reconstr Surg. 2018 Nov;142(5):787e-789e. doi: 10.1097/PRS.0000000000004947.PMID: 30512000

​

Clinical evidence supporting genomic tests in early breast cancer: Do all genomic tests provide the same information?

Markopoulos C, van de Velde C, Zarca D, Ozmen V, Masetti R.

Eur J Surg Oncol. 2016 Aug 31. pii: S0748-7983(16)30857-5. doi: 10.1016/j.ejso.2016.08.012. [Epub ahead of print]

​

Integration of a Radiosensitivity Molecular Signature Into the Assessment of Local Recurrence Risk in Breast Cancer.

Torres-Roca JF, Fulp WJ, Caudell JJ, Servant N, Bollet MA, van de Vijver M, Naghavi AO, Harris EE, Eschrich SA.

Int J Radiat Oncol Biol Phys. 2015 Nov 1;93(3):631-8. doi: 10.1016/j.ijrobp.2015.06.021. Epub 2015 Jun 25.

​

Comparison between two different algorithms used for pretreatment QA via aSi portal images.

Merheb C, Chevillard C, Ksouri W, Fawzi M, Bollet M, Toledano A.

J Appl Clin Med Phys. 2015 May 8;16(3):5202. doi: 10.1120/jacmp.v16i3.5202.

 

Late toxicities and outcomes of adjuvant radiotherapy combined with concurrent bevacizumab in patients with triple-negative non-metastatic breast cancer.

Pernin V, Belin L, Cottu P, Bontemps P, Lemanski C, De La Lande B, Baumann P, Missohou F, Levy C, Peignaux K, Reynaud-Bougnoux A, Denis F, Gobillion A, Bollet M, Vago NA, Dendale R, Campana F, Fourquet A, Kirova YM.

Br J Radiol. 2015 Apr;88(1048):20140800. doi: 10.1259/bjr.20140800. Epub 2015 Feb 3.

​

Radiotherapy associated with concurrent bevacizumab in patients with non-metastatic breast cancer.

Pernin V, Belin L, Cottu P, Bontemps P, Lemanski C, De La Lande B, Baumann P, Missohou F, Levy C, Peignaux K, Bougnoux P, Denis F, Bollet M, Dendale R, Vago NA, Campana F, Fourquet A, Kirova YM.

Breast. 2014 Dec;23(6):816-20. doi: 10.1016/j.breast.2014.08.015. Epub 2014 Sep 26.

​

Management of somatic pain induced by head and neck cancer treatment: pain following radiation therapy and chemotherapy. Guidelines of the French Otorhinolaryngology Head and Neck Surgery Society (SFORL).

Blanchard D, Bollet M, Dreyer C, Binczak M, Calmels P, Couturaud C, Espitalier F, Navez M, Perrichon C, Testelin S, Albert S, Morinière S; SFORL Work Group.

Eur Ann Otorhinolaryngol Head Neck Dis. 2014 Sep;131(4):253-6. doi: 10.1016/j.anorl.2014.07.001. Epub 2014 Aug 4.

​

Histological grade concordance between diagnostic core biopsy and corresponding surgical specimen in HR-positive/HER2-negative breast carcinoma.

Daveau C, Baulies S, Lalloum M, Bollet M, Sigal-Zafrani B, Sastre X, Vincent-Salomon A, Tardivon A, Thibault F, Pierga JY, Cottu P, Sablin MP, Rouzier R, Malhaire C, Mallon P, Reyal F.

Br J Cancer. 2014 Apr 29;110(9):2195-200. doi: 10.1038/bjc.2014.143. Epub 2014 Apr 8.

​

Extensive pure ductal carcinoma in situ of the breast: identification of predictors of associated infiltrating carcinoma and lymph node metastasis before immediate reconstructive surgery.

Guillot E, Vaysse C, Goetgeluck J, Falcou MC, Couturaud B, Fitoussi A, Fourchotte V, Laki F, Malhaire C, Sigal-Zafrani B, Sastre-Garau X, Bollet MA, Mosseri V, Reyal F.

Breast. 2014 Apr;23(2):97-103. doi: 10.1016/j.breast.2013.12.002. Epub 2013 Dec 31.

​

Loss of heterozygosity at 13q13 and 14q32 predicts BRCA2 inactivation in luminal breast carcinomas.

Pécuchet N, Popova T, Manié E, Lucchesi C, Battistella A, Vincent-Salomon A, Caux-Moncoutier V, Bollet M, Sigal-Zafrani B, Sastre-Garau X, Stoppa-Lyonnet D, Stern MH.

Int J Cancer. 2013 Dec 15;133(12):2834-42. doi: 10.1002/ijc.28315. Epub 2013 Jul 10.

 

Long-term prognostic performance of Ki67 rate in early stage, pT1-pT2, pN0, invasive breast carcinoma.

Reyal F, Hajage D, Savignoni A, Feron JG, Bollet MA, Kirova Y, Fourquet A, Pierga JY, Cottu P, Dieras V, Fourchotte V, Laki F, Alran S, Asselain B, Vincent-Salomon A, Sigal-Zafrani B, Sastre-Garau X.

PLoS One. 2013;8(3):e55901. doi: 10.1371/journal.pone.0055901. Epub 2013 Mar 19.

​

Prospective monocentric study of the toxicity and the efficacy of concurrent trastuzumab and radiotherapy].

Jacob J, Belin L, Gobillion A, Daveau-Bergerault C, Dendale R, Beuzeboc P, Campana F, Bollet MA, Fourquet A, Kirova YM.

Cancer Radiother. 2013 Jun;17(3):183-90. doi: 10.1016/j.canrad.2012.12.006. Epub 2013 Mar 15. French.

​

Infiltrating lobular breast cancer: truly a separate entity! Consequences for radiation therapy.

Poortmans PM, Bollet M, Van Limbergen E.

Radiother Oncol. 2013 Jan;106(1):1-4. doi: 10.1016/j.radonc.2012.12.010. Epub 2013 Jan 22.

​

[A case of cutaneous mammary re-irradiation].

Jacob J, Pierga JY, Fourchotte V, Kirova YM, Bollet MA.

Cancer Radiother. 2012 Oct;16(7):638-40. doi: 10.1016/j.canrad.2012.08.002. Epub 2012 Oct 23. French.

 

Adjuvant radiotherapy in the management of axillary node negative invasive breast cancer: a qualitative systematic review.

Bourgier C, Aimard L, Bodez V, Bollet MA, Cutuli B, Franck D, Hennequin C, Kirova YM, Azria D.

Crit Rev Oncol Hematol. 2013 Apr;86(1):33-41. doi: 10.1016/j.critrevonc.2012.09.010. Epub 2012 Oct 22. Review.

​

Ploidy and large-scale genomic instability consistently identify basal-like breast carcinomas with BRCA1/2 inactivation.

Popova T, Manié E, Rieunier G, Caux-Moncoutier V, Tirapo C, Dubois T, Delattre O, Sigal-Zafrani B, Bollet M, Longy M, Houdayer C, Sastre-Garau X, Vincent-Salomon A, Stoppa-Lyonnet D, Stern MH.

Cancer Res. 2012 Nov 1;72(21):5454-62. doi: 10.1158/0008-5472.CAN-12-1470. Epub 2012 Aug 29.

​

Concurrent use of aromatase inhibitors and hypofractionated radiation therapy.

Chargari C, Castro-Pena P, Toledano I, Bollet MA, Savignoni A, Cottu P, Laki F, Campana F, De Cremoux P, Fourquet A, Kirova YM.

World J Radiol. 2012 Jul 28;4(7):318-23. doi: 10.4329/wjr.v4.i7.318.

​

New strategy in hepatic metastatic colorectal cancer: tomotherapy and capecitabine followed by hepatic surgical resection.

Cacheux W, Bollet MA, Servois V, Zefkili S, Farkhondeh F, Baranger B, Mariani P.

Med Oncol. 2012 Dec;29(5):3143-6. doi: 10.1007/s12032-012-0311-z. Epub 2012 Aug 2.

​

Prospective and comparative evaluation of the toxicity of adjuvant concurrent chemoradiotherapy after neoadjuvant chemotherapy for breast cancer.

Marchand V, Angelergues A, Gobaux V, Hajage D, Kirova YM, Campana F, Dendale R, Reyal F, Pierga JY, Fourquet A, Bollet MA.

Am J Clin Oncol. 2013 Oct;36(5):425-9. doi: 10.1097/COC.0b013e31825466a6.

​

Respective prognostic value of genomic grade and histological proliferation markers in early stage (pN0) breast carcinoma.

Reyal F, Bollet MA, Caly M, Gentien D, Carpentier S, Peyro-Saint-Paul H, Pierga JY, Cottu P, Dieras V, Sigal-Zafrani B, Vincent-Salomon A, Sastre-Garau X.

PLoS One. 2012;7(4):e35184. doi: 10.1371/journal.pone.0035184. Epub 2012 Apr 18. Erratum in: PLoS One. 2012;7(7). doi: 10.1371/annotation/46dc7048-61b1-45bd-b4cd-a3b80a2f3f5a.

​

[Breast conserving surgery in locoregional treatment of breast carcinoma after Hodgkin lymphoma].

Haberer S, Belin L, Le Scodan R, Kirova YM, Savignoni A, Stevens D, Moisson P, Decaudin D, Pierga JY, Reyal F, Campana F, Fourquet A, Bollet MA.

Cancer Radiother. 2012 Apr;16(2):128-35. doi: 10.1016/j.canrad.2011.10.013. Epub 2012 Feb 15. French.

​

Search for a gene expression signature of breast cancer local recurrence in young women.

Servant N, Bollet MA, Halfwerk H, Bleakley K, Kreike B, Jacob L, Sie D, Kerkhoven RM, Hupé P, Hadhri R, Fourquet A, Bartelink H, Barillot E, Sigal-Zafrani B, van de Vijver MJ.

Clin Cancer Res. 2012 Mar 15;18(6):1704-15. doi: 10.1158/1078-0432.CCR-11-1954. Epub 2012 Jan 23.

 

External validation of Adjuvant! Online breast cancer prognosis tool. Prioritising recommendations for improvement.

Hajage D, de Rycke Y, Bollet M, Savignoni A, Caly M, Pierga JY, Horlings HM, Van de Vijver MJ, Vincent-Salomon A, Sigal-Zafrani B, Senechal C, Asselain B, Sastre X, Reyal F.

PLoS One. 2011;6(11):e27446. doi: 10.1371/journal.pone.0027446. Epub 2011 Nov 8.

​

Preoperative radio-chemotherapy in early breast cancer patients: long-term results of a phase II trial.

Bollet MA, Belin L, Reyal F, Campana F, Dendale R, Kirova YM, Thibault F, Diéras V, Sigal-Zafrani B, Fourquet A.

Radiother Oncol. 2012 Jan;102(1):82-8. doi: 10.1016/j.radonc.2011.08.017. Epub 2011 Sep 8.

​

[Role of locoregional radiation therapy in breast cancer patients with negative lymph nodes after preoperative chemotherapy and mastectomy. The Institut Curie-Hôpital René-Huguenin experience].

Le Scodan R, Bruant S, Selz J, Bollet MA, Daveau C, de la Lande B, Lerebours F, Labib A, Stevens D.

Cancer Radiother. 2011 Dec;15(8):675-82. doi: 10.1016/j.canrad.2011.04.004. Epub 2011 Aug 9. French.

​

[Management of inflammatory breast cancer after neo-adjuvant chemotherapy].

Abrous-Anane S, Savignoni A, Daveau C, Pierga JY, Gautier C, Reyal F, Dendale R, Campana F, Kirova Y, Fourquet A, Bollet MA.

Cancer Radiother. 2011 Dec;15(8):654-62. doi: 10.1016/j.canrad.2011.01.009. Epub 2011 Aug 5. French.

​

The molecular subtype classification is a determinant of sentinel node positivity in early breast carcinoma.

Reyal F, Rouzier R, Depont-Hazelzet B, Bollet MA, Pierga JY, Alran S, Salmon RJ, Fourchotte V, Vincent-Salomon A, Sastre-Garau X, Antoine M, Uzan S, Sigal-Zafrani B, De Rycke Y.

PLoS One. 2011;6(5):e20297. doi: 10.1371/journal.pone.0020297. Epub 2011 May 31.

​

Preliminary experience of whole-brain radiation therapy (WBRT) in breast cancer patients with brain metastases previously treated with bevacizumab-based chemotherapy.

Chira C, Jacob J, Derhem N, Bollet MA, Campana F, Marchand V, Pierga JY, Fourquet A, Kirova YM.

J Neurooncol. 2011 Nov;105(2):401-8. doi: 10.1007/s11060-011-0607-4. Epub 2011 Jun 5.

​

Can we decrease the skin reaction in breast cancer patients using hyaluronic acid during radiation therapy? Results of phase III randomised trial.

Kirova YM, Fromantin I, De Rycke Y, Fourquet A, Morvan E, Padiglione S, Falcou MC, Campana F, Bollet MA.

Radiother Oncol. 2011 Aug;100(2):205-9. doi: 10.1016/j.radonc.2011.05.014. Epub 2011 May 31.

​

Locoregional treatment for breast carcinoma after Hodgkin's lymphoma: the breast conservation option.

Haberer S, Belin L, Le Scodan R, Kirova YM, Savignoni A, Stevens D, Moisson P, Decaudin D, Pierga JY, Reyal F, Campana F, Fourquet A, Bollet MA.

Int J Radiat Oncol Biol Phys. 2012 Feb 1;82(2):e145-52. doi: 10.1016/j.ijrobp.2011.03.013. Epub 2011 May 24.

​

[Concurrent whole-brain radiotherapy with trastuzumab for treatment of brain metastases in breast cancer patients: questions and answers].

Riahi Idrissi H, Chargari C, Bollet MA, Le Scodan R, Olivier L, Dorval T, Marchand V, Cottu P, Dieras V, Campana F, Fourquet A, Kirova YM.

Bull Cancer. 2011 Apr;98(4):425-32. doi: 10.1684/bdc.2011.1342. Review. French.

​

[Radiotherapy for breast cancer and pacemaker].

Menard J, Campana F, Kirov KM, Bollet MA, Dendale R, Fournier-Bidoz N, Marchand V, Mazal A, Estève M, Fourquet A, Kirova YM.

Cancer Radiother. 2011 Jun;15(3):197-201. doi: 10.1016/j.canrad.2010.11.014. Epub 2011 Mar 21. French.

 

High levels of anti-cyclic citrullinated peptide autoantibodies are associated with co-occurrence of pulmonary diseases with rheumatoid arthritis.

Aubart F, Crestani B, Nicaise-Roland P, Tubach F, Bollet C, Dawidowicz K, Quintin E, Hayem G, Palazzo E, Meyer O, Chollet-Martin S, Dieudé P.

J Rheumatol. 2011 Jun;38(6):979-82. doi: 10.3899/jrheum.101261. Epub 2011 Mar 1.

​

Radiotherapy for stage II and stage III breast cancer patients with negative lymph nodes after preoperative chemotherapy and mastectomy.

Le Scodan R, Selz J, Stevens D, Bollet MA, de la Lande B, Daveau C, Lerebours F, Labib A, Bruant S.

Int J Radiat Oncol Biol Phys. 2012 Jan 1;82(1):e1-7. doi: 10.1016/j.ijrobp.2010.12.054. Epub 2011 Mar 4.

 

Management of phyllodes breast tumors.

Guillot E, Couturaud B, Reyal F, Curnier A, Ravinet J, Laé M, Bollet M, Pierga JY, Salmon R, Fitoussi A; Breast Cancer Study Group of the Institut Curie.

Breast J. 2011 Mar-Apr;17(2):129-37. doi: 10.1111/j.1524-4741.2010.01045.x. Epub 2011 Jan 19.

 

[Early stage breast cancer: is exclusive radiotherapy an option for early breast cancers with complete clinical response after neoadjuvant chemotherapy?].

Daveau C, Savignoni A, Abrous-Anane S, Pierga JY, Reyal F, Gautier C, Kirova YM, Dendale R, Campana F, Fourquet A, Bollet MA.

Cancer Radiother. 2011 Apr;15(2):106-14. doi: 10.1016/j.canrad.2010.06.020. Epub 2010 Nov 16. French.

 

Preliminary results of whole brain radiotherapy with concurrent trastuzumab for treatment of brain metastases in breast cancer patients.

Chargari C, Idrissi HR, Pierga JY, Bollet MA, Diéras V, Campana F, Cottu P, Fourquet A, Kirova YM.

Int J Radiat Oncol Biol Phys. 2011 Nov 1;81(3):631-6. doi: 10.1016/j.ijrobp.2010.06.057. Epub 2010 Oct 6.

​

Cardiac toxicity in breast cancer patients: from a fractional point of view to a global assessment.

Chargari C, Kirov KM, Bollet MA, Magné N, Védrine L, Cremades S, Beuzeboc P, Fourquet A, Kirova YM.

Cancer Treat Rev. 2011 Jun;37(4):321-30. doi: 10.1016/j.ctrv.2010.08.007. Epub 2010 Sep 22. Review.

​

The acute skin and heart toxicity of a concurrent association of trastuzumab and locoregional breast radiotherapy including internal mammary chain: a single-institution study.

Caussa L, Kirova YM, Gault N, Pierga JY, Savignoni A, Campana F, Dendale R, Fourquet A, Bollet MA.

Eur J Cancer. 2011 Jan;47(1):65-73. doi: 10.1016/j.ejca.2010.08.013. Epub 2010 Sep 16.

​

Prognostic factors for local recurrence following breast-conserving treatment in young women.

Bollet MA, Kirova YM, Fourquet A, de Cremoux P, Reyal F.

Expert Rev Anticancer Ther. 2010 Aug;10(8):1215-27. doi: 10.1586/era.10.67. Review.

​

Targeting poly(ADP-ribose) polymerase activity for cancer therapy.

Mégnin-Chanet F, Bollet MA, Hall J.

Cell Mol Life Sci. 2010 Nov;67(21):3649-62. doi: 10.1007/s00018-010-0490-8. Epub 2010 Aug 20. Review.

PMID: 20725763 [PubMed - indexed for MEDLINE] Free PMC Article

 

Analysis of the copy number profiles of several tumor samples from the same patient reveals the successive steps in tumorigenesis.

Letouzé E, Allory Y, Bollet MA, Radvanyi F, Guyon F.

Genome Biol. 2010;11(7):R76. doi: 10.1186/gb-2010-11-7-r76. Epub 2010 Jul 22.

​

Is radiotherapy an option for early breast cancers with complete clinical response after neoadjuvant chemotherapy?

Daveau C, Savignoni A, Abrous-Anane S, Pierga JY, Reyal F, Gautier C, Kirova YM, Dendale R, Campana F, Fourquet A, Bollet MA.

Int J Radiat Oncol Biol Phys. 2011 Apr 1;79(5):1452-9. doi: 10.1016/j.ijrobp.2010.01.003. Epub 2010 Jun 3.

​

The impact of the loco-regional treatment in elderly breast cancer patients: hypo-fractionated exclusive radiotherapy, single institution long-term results.

Chargari C, Kirova YM, Laki F, Savignoni A, Dorval T, Dendale R, Bollet MA, Fourquet A, Campana F; Institut Curie Breast Cancer Study Group.

Breast. 2010 Oct;19(5):413-6. doi: 10.1016/j.breast.2010.04.004. Epub 2010 May 18.

​

Management of inflammatory breast cancer after neoadjuvant chemotherapy.

Abrous-Anane S, Savignoni A, Daveau C, Pierga JY, Gautier C, Reyal F, Dendale R, Campana F, Kirova YM, Fourquet A, Bollet MA.

Int J Radiat Oncol Biol Phys. 2011 Mar 15;79(4):1055-63. doi: 10.1016/j.ijrobp.2009.12.009. Epub 2010 May 17.

​

Improving the definition of tumor bed boost with the use of surgical clips and image registration in breast cancer patients.

Kirova YM, Castro Pena P, Hijal T, Fournier-Bidoz N, Laki F, Sigal-Zafrani B, Dendale R, Bollet MA, Campana F, Fourquet A.

Int J Radiat Oncol Biol Phys. 2010 Dec 1;78(5):1352-5. doi: 10.1016/j.ijrobp.2009.10.049. Epub 2010 Apr 8.

​

Simultaneous integrated boost in breast conserving treatment of breast cancer: a dosimetric comparison of helical tomotherapy and three-dimensional conformal radiotherapy.

Hijal T, Fournier-Bidoz N, Castro-Pena P, Kirova YM, Zefkili S, Bollet MA, Dendale R, Campana F, Fourquet A.

Radiother Oncol. 2010 Mar;94(3):300-6. doi: 10.1016/j.radonc.2009.12.043. Epub 2010 Feb 18.

 

Delayed reaction after adjuvant whole breast radiotherapy at the dose of 42.9 Gy in 13 fractions over 5 weeks: the need for rapid post irradiation clinical assessment and who are the patients at risk?

Kirova YM, Botti M, Campana F, Dendale R, Zervoudis S, Kyrias G, Bollet MA, Fourquet A.

J BUON. 2009 Oct-Dec;14(4):729-30. No abstract available.

​

Prevalence of autoantibodies in SAPHO syndrome: a single-center study of 90 patients.

Grosjean C, Hurtado-Nedelec M, Nicaise-Roland P, Ferreyra-Dillon R, Bollet C, Quintin E, Dieude P, Palazzo E, Wattiaux MJ, Kahn MF, Meyer O, Chollet-Martin S, Hayem G.

J Rheumatol. 2010 Mar;37(3):639-43. doi: 10.3899/jrheum.090863. Epub 2010 Jan 28.

​

Technique alternatives for breast radiation oncology: Conventional radiation therapy to tomotherapy.

Fournier-Bidoz N, Kirova Y, Campana F, El Barouky J, Zefkili S, Dendale R, Bollet MA, Mazal A, Fourquet A.

J Med Phys. 2009 Jul;34(3):149-52. doi: 10.4103/0971-6203.54849.

​

Simplified rules for everyday delineation of lymph node areas for breast cancer radiotherapy.

Kirova YM, Castro Pena P, Dendale R, Servois V, Bollet MA, Fournier-Bidoz N, Campana F, Fourquet A.

Br J Radiol. 2010 Aug;83(992):683-6. doi: 10.1259/bjr/28834220. Epub 2009 Dec 17.

​

Tumor aromatase expression as a prognostic factor for local control in young breast cancer patients after breast-conserving treatment.

Bollet MA, Savignoni A, De Koning L, Tran-Perennou C, Barbaroux C, Degeorges A, Sigal-Zafrani B, Almouzni G, Cottu P, Salmon R, Servant N, Fourquet A, de Cremoux P.

Breast Cancer Res. 2009;11(4):R54. doi: 10.1186/bcr2343. Epub 2009 Jul 28.

​

[Definition of nodal volumes in breast cancer treatment and segmentation guidelines].

Kirova YM, Castro Pena P, Dendale R, Campana F, Bollet MA, Fournier-Bidoz N, Fourquet A.

J Radiol. 2009 Jun;90(6):747-51. French.

​

[Management of malignant phyllodes tumors of the breast: the experience of the Institut Curie].

Haberer S, Laé M, Seegers V, Pierga JY, Salmon R, Kirova YM, Dendale R, Campana F, Reyal F, Miranda O, Fourquet A, Bollet MA.

Cancer Radiother. 2009 Jul;13(4):305-12. doi: 10.1016/j.canrad.2009.05.001. Epub 2009 Jun 12. French.

​

[Monocentric evaluation of the skin and cardiac toxicities of the concomitant administration of trastuzumab and radiotherapy].

Kirova YM, Caussa L, Granger B, Savignoni A, Dendale R, Campana F, Tournat H, Pierga JY, Fourquet A, Bollet MA.

Cancer Radiother. 2009 Jul;13(4):276-80. doi: 10.1016/j.canrad.2009.02.008. Epub 2009 May 17. French.

​

Urokinase-type plasminogen activator and plasminogen-activator-inhibitor type 1 predict metastases in good prognosis breast cancer patients.

De Cremoux P, Grandin L, Diéras V, Savignoni A, Degeorges A, Salmon R, Bollet MA, Reyal F, Sigal-Zafrani B, Vincent-Salomon A, Sastre-Garau X, Magdelénat H, Mignot L, Fourquet A; Breast Cancer Study Group of the Institut Curie.

Anticancer Res. 2009 May;29(5):1475-82.

​

Ductal carcinoma in situ of the breast with close or focally involved margins following breast-conserving surgery: treatment with reexcision or radiotherapy with increased dosage.

Monteau A, Sigal-Zafrani B, Kirova YM, Fourchotte V, Bollet MA, Vincent-Salomon A, Asselain B, Salmon RJ, Fourquet A.

Int J Radiat Oncol Biol Phys. 2009 Nov 15;75(4):1021-8. doi: 10.1016/j.ijrobp.2008.12.014. Epub 2009 Apr 20.

​

Anatomical, clinical and radiological delineation of target volumes in breast cancer radiotherapy planning: individual variability, questions and answers.

Castro Pena P, Kirova YM, Campana F, Dendale R, Bollet MA, Fournier-Bidoz N, Fourquet A.

Br J Radiol. 2009 Jul;82(979):595-9. doi: 10.1259/bjr/96865511. Epub 2009 Mar 2.

​

Breast-conserving treatment in the elderly: long-term results of adjuvant hypofractionated and normofractionated radiotherapy.

Kirova YM, Campana F, Savignoni A, Laki F, Muresan M, Dendale R, Bollet MA, Salmon RJ, Fourquet A; Institut Curie Breast Cancer Study Group.

Int J Radiat Oncol Biol Phys. 2009 Sep 1;75(1):76-81. doi: 10.1016/j.ijrobp.2008.11.005. Epub 2009 Jan 23.

​

[Hypofractionated breast radiotherapy in 13 fractions, perfect tolerance or delayed early reaction? Prospective study of Curie Institute].

Botti M, Kirova YM, Dendale R, Savignoni A, Fromantin I, Gautier C, Bollet MA, Campana F, Fourquet A.

Cancer Radiother. 2009 Apr;13(2):92-6. doi: 10.1016/j.canrad.2008.11.009. Epub 2009 Jan 23. French.

​

[Shared responsibility for follow-up of breast cancer patients. Experience of the Institut Curie].

Chargari C, Kirova Y, Bollet M, Sigal-Zafrani B, Dendale R, Rizand P, de la Rochefordiere A, Fourquet A, Campana F.

Bull Cancer. 2008 Nov;95(11):1047-51. doi: 10.1684/bdc.2008.0746. French.

​

[Meta-analyses of the effects of radiotherapy in breast cancer: the ultimate evidence?].

Fourquet A, Kirova Y, Bollet MA, Tournat H, Dendale R, Campana F.

Cancer Radiother. 2008 Nov;12(6-7):554-8. doi: 10.1016/j.canrad.2008.08.279. Epub 2008 Oct 1. French.

​

The use of computed tomography in radiotherapy treatment planning for breast cancer. How does conventional radiotherapy planning compare with virtual?

Bauduceau O, Bollet MA, Pons P, Kirova YM, Fayolle M, Zervoudis S, Campana F.

J BUON. 2008 Apr-Jun;13(2):245-51.

​

How to boost the breast tumor bed? A multidisciplinary approach in eight steps.

Kirova YM, Fournier-Bidoz N, Servois V, Laki F, Pollet GA, Salmon R, Thomas A, Dendale R, Bollet MA, Campana F, Fourquet A.

Int J Radiat Oncol Biol Phys. 2008 Oct 1;72(2):494-500. doi: 10.1016/j.ijrobp.2007.12.059. Epub 2008 Apr 18.

​

High rates of breast conservation for large ductal and lobular invasive carcinomas combining multimodality strategies.

Bollet MA, Savignoni A, Pierga JY, Lae M, Fourchotte V, Kirova YM, Dendale R, Campana F, Sigal-Zafrani B, Salmon R, Fourquet A, Vincent-Salomon A.

Br J Cancer. 2008 Feb 26;98(4):734-41. doi: 10.1038/sj.bjc.6604229. Epub 2008 Feb 5.

​

High-resolution mapping of DNA breakpoints to define true recurrences among ipsilateral breast cancers.

Bollet MA, Servant N, Neuvial P, Decraene C, Lebigot I, Meyniel JP, De Rycke Y, Savignoni A, Rigaill G, Hupé P, Fourquet A, Sigal-Zafrani B, Barillot E, Thiery JP.

J Natl Cancer Inst. 2008 Jan 2;100(1):48-58. Epub 2007 Dec 25.

​

Responses to concurrent radiotherapy and hormone-therapy and outcome for large breast cancers in post-menopausal women.

Bollet MA, Kirova YM, Antoni G, Pierga JY, Sigal-Zafrani B, Laki F, Campana F, Dendale R, Salmon R, Cottu P, Fourquet A.

Radiother Oncol. 2007 Dec;85(3):336-45. Epub 2007 Oct 29.

​

Are ipsilateral breast tumour invasive recurrences in young women more aggressive than their primary tumours?

Sigal-Zafrani B, Bollet MA, Antoni G, Savignoni A, Vincent-Salomon A, Pierga JY, Salmon R, Sastre-Garau X, Fourquet A.

Br J Cancer. 2007 Oct 22;97(8):1046-52. Epub 2007 Sep 18.

​

Postmastectomy electron beam chest wall irradiation in women with breast cancer: a clinical step toward conformal electron therapy.

Kirova YM, Campana F, Fournier-Bidoz N, Stilhart A, Dendale R, Bollet MA, Fourquet A.

Int J Radiat Oncol Biol Phys. 2007 Nov 15;69(4):1139-44. Epub 2007 Aug 6.

​

Role of dynamic magnetic resonance imaging in the evaluation of tumor response to preoperative concurrent radiochemotherapy for large breast cancers: a prospective phase II study.

Bollet MA, Thibault F, Bouillon K, Meunier M, Sigal-Zafrani B, Savignoni A, Diéras V, Nos C, Salmon R, Fourquet A; Institut Curie Breast Cancer Study Group.

Int J Radiat Oncol Biol Phys. 2007 Sep 1;69(1):13-8. Epub 2007 Apr 20.

​

Does concurrent radiochemotherapy affect cosmetic results in the adjuvant setting after breast-conserving surgery? Results of the ARCOSEIN multicenter, Phase III study: patients' and doctors' views.

Toledano AH, Bollet MA, Fourquet A, Azria D, Gligorov J, Garaud P, Serin D, Bosset JF, Miny-Buffet J, Favre A, LeFoch O, Calais G.

Int J Radiat Oncol Biol Phys. 2007 May 1;68(1):66-72.

​

Age remains the first prognostic factor for loco-regional breast cancer recurrence in young (<40 years) women treated with breast conserving surgery first.

Bollet MA, Sigal-Zafrani B, Mazeau V, Savignoni A, de la Rochefordière A, Vincent-Salomon A, Salmon R, Campana F, Kirova YM, Dendale R, Fourquet A.

Radiother Oncol. 2007 Mar;82(3):272-80. Epub 2007 Feb 6. Erratum in: Radiother Oncol. 2007 May;83(2):215.

​

Demineralisation of permeable hydroxyapatite with alternating water and acidic buffer: scanning microradiographic study of effect of switching period.

Bollet-Quivogne FR, Anderson P, Dowker SE, Elliott JC.

Caries Res. 2007;41(2):152-60.

​

Pathological response to preoperative concurrent chemo-radiotherapy for breast cancer: results of a phase II study.

Bollet MA, Sigal-Zafrani B, Gambotti L, Extra JM, Meunier M, Nos C, Dendale R, Campana F, Kirova YM, Diéras V, Fourquet A; Institut Curie Breast Cancer Study Group.

Eur J Cancer. 2006 Sep;42(14):2286-95. Epub 2006 Aug 8.

​

Breast radiotherapy in women with pectus excavatum (funnel chest): is the lateral decubitus technique an answer? A dosimetric study.

Bollet MA, Campana F, Kirova YM, Dendale R, Saliou MG, Rosenwald JC, Fourquet A.

Br J Radiol. 2006 Oct;79(946):785-90. Epub 2006 Jul 5.

​

CT-scan based localization of the internal mammary chain and supra clavicular nodes for breast cancer radiation therapy planning.

Kirova YM, Servois V, Campana F, Dendale R, Bollet MA, Laki F, Fournier-Bidoz N, Fourquet A.

Radiother Oncol. 2006 Jun;79(3):310-5. Epub 2006 Jun 12.

​

Treatment of squamous cell anal canal carcinoma (SCACC) with pulsed dose rate brachytherapy: a retrospective study.

Bruna A, Gastelblum P, Thomas L, Chapet O, Bollet MA, Ardiet JM, Gérard JP, Peiffert D.

Radiother Oncol. 2006 Apr;79(1):75-9.

​

[Radiation-induced sarcomas after breast cancer: experience of Institute Curie and review of literature].

Kirova Y, Vilcoq JR, Asselain B, Sastre-Garau X, Campana F, Dendale R, Bollet M, Fourquet A.

Cancer Radiother. 2006 Feb-Mar;10(1-2):83-90. Epub 2005 Nov 21. Review. French.

​

[Comparison of classic simulation and virtual simulation in breast irradiation: prospective study on 14 patients].

Bauduceau O, Pons P, Campana F, Bollet M, Romero L, Fayolle M.

Cancer Radiother. 2005 Nov;9(6-7):402-10. Epub 2005 Oct 12. French.

​

Functional outcome of patients with benign meningioma treated by 3D conformal irradiation with a combination of photons and protons.

Noël G, Bollet MA, Calugaru V, Feuvret L, Haie-Meder C, Dhermain F, Ferrand R, Boisserie G, Beaudré A, Mazeron JJ, Habrand JL.

Int J Radiat Oncol Biol Phys. 2005 Aug 1;62(5):1412-22.

​

Linac stereotactic radiosurgery: an effective and safe treatment for elderly patients with brain metastases.

Noel G, Bollet MA, Noel S, Feuvret L, Boisserie G, Tep B, Delattre JY, Baillet F, Ambroise Valery C, Cornu P, Mazeron JJ.

Int J Radiat Oncol Biol Phys. 2005 Dec 1;63(5):1555-61. Epub 2005 Jul 18.

​

Efficacy and morbidity of arc-therapy radiosurgery for cerebral arteriovenous malformations: a comparison with the natural history.

Bollet MA, Anxionnat R, Buchheit I, Bey P, Cordebar A, Jay N, Desandes E, Marchal C, Lapeyre M, Aletti P, Picard L.

Int J Radiat Oncol Biol Phys. 2004 Apr 1;58(5):1353-63. Review.

​

Postoperative brachytherapy alone and combined postoperative radiotherapy and brachytherapy boost for squamous cell carcinoma of the oral cavity, with positive or close margins.

Lapeyre M, Bollet MA, Racadot S, Geoffrois L, Kaminsky MC, Hoffstetter S, Dolivet G, Toussaint B, Luporsi E, Peiffert D.

Head Neck. 2004 Mar;26(3):216-23.

​

Can digitally reconstructed radiographs (DRRS) replace simulation films in prostate cancer conformal radiotherapy?

Bollet MA, McNair HA, Hansen VN, Norman A, O'Doherty U, Taylor H, Rose M, Mukherjee R, Huddart R.

Int J Radiat Oncol Biol Phys. 2003 Nov 15;57(4):1122-30.

​

Radiotherapy treatment planning of prostate cancer using magnetic resonance imaging alone.

Lee YK, Bollet M, Charles-Edwards G, Flower MA, Leach MO, McNair H, Moore E, Rowbottom C, Webb S.

Radiother Oncol. 2003 Feb;66(2):203-16.

​

Cervical lymph node relapses of head-and-neck squamous cell carcinoma: is brachytherapy a therapeutic option?

Bollet MA, Lapeyre M, Marchal C, Hoffstetter S, Peiffert D, Cornes PG, Luporsi E, Bey P.

Int J Radiat Oncol Biol Phys. 2001 Dec 1;51(5):1305-12.

 

[Perception of pT1a,b pN0 breast tumor prognosis by the French oncology community: Results of the EURISTIC national survey].

Spielmann M, Dalenc F, Pointreau Y, Azria D, Classe JM, Dromain C, Facchini T, Gonçalves A, Liegeois P, Namer M, Pivot X, Vincent-Salomon A.

Bull Cancer. 2016 Feb;103(2):154-63. doi: 10.1016/j.bulcan.2015.10.007. Epub 2015 Dec 2. French.

​

Combined evaluation of LC3B puncta and HMGB1 expression predicts residual risk of relapse after adjuvant chemotherapy in breast cancer.

Ladoire S, Penault-Llorca F, Senovilla L, Dalban C, Enot D, Locher C, Prada N, Poirier-Colame V, Chaba K, Arnould L, Ghiringhelli F, Fumoleau P, Spielmann M, Delaloge S, Poillot ML, Arveux P, Goubar A, Andre F, Zitvogel L, Kroemer G.

Autophagy. 2015 Oct 3;11(10):1878-90. doi: 10.1080/15548627.2015.1082022.

​

Coexpression of androgen receptor and FOXA1 in nonmetastatic triple-negative breast cancer: ancillary study from PACS08 trial.

Guiu S, Charon-Barra C, Vernerey D, Fumoleau P, Campone M, Spielmann M, Roché H, Mesleard C, Arnould L, Lemonnier J, Lacroix-Triki M.

Future Oncol. 2015;11(16):2283-97. doi: 10.2217/fon.15.102.

​

Efficacy of Adjuvant Trastuzumab for Patients With Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer and Tumors ≤ 2 cm: A Meta-Analysis of the Randomized Trastuzumab Trials.

O'Sullivan CC, Bradbury I, Campbell C, Spielmann M, Perez EA, Joensuu H, Costantino JP, Delaloge S, Rastogi P, Zardavas D, Ballman KV, Holmes E, de Azambuja E, Piccart-Gebhart M, Zujewski JA, Gelber RD.

J Clin Oncol. 2015 Aug 20;33(24):2600-8. doi: 10.1200/JCO.2015.60.8620. Epub 2015 Jun 22.

​

Relations between arthralgia and fear of recurrence: results of a cross-sectional study of breast cancer patients treated with adjuvant aromatase inhibitors therapy.

Lopez C, Charles C, Rouby P, Boinon D, Laurent S, Rey A, Spielmann M, Dauchy S.

Support Care Cancer. 2015 Dec;23(12):3581-8. doi: 10.1007/s00520-015-2722-9. Epub 2015 Apr 17.

​

Effect of obesity on disease-free and overall survival in node-positive breast cancer patients in a large French population: a pooled analysis of two randomised trials.

Ladoire S, Dalban C, Roché H, Spielmann M, Fumoleau P, Levy C, Martin AL, Ecarnot F, Bonnetain F, Ghiringhelli F.

Eur J Cancer. 2014 Feb;50(3):506-16. doi: 10.1016/j.ejca.2013.11.013. Epub 2013 Dec 4.

​

Prognostic factors of young women (≤ 35 years) with node positive breast cancer: possible influence on post-therapeutic follow-up.

Filleron T, Md FD, Kramar A, Spielmann M, Levy C, Fumoleau P, Canon JL, Martin AL, Roché H.

Bull Cancer. 2013 Jul-Aug;100(7-8):22-9. doi: 10.1684/bdc.2013.1791.

​

Correlation of HER2, FCGR2A, and FCGR3A gene polymorphisms with trastuzumab related cardiac toxicity and efficacy in a subgroup of patients from UNICANCER-PACS 04 trial.

Roca L, Diéras V, Roché H, Lappartient E, Kerbrat P, Cany L, Chieze S, Canon JL, Spielmann M, Penault-Llorca F, Martin AL, Mesleard C, Lemonnier J, de Cremoux P.

Breast Cancer Res Treat. 2013 Jun;139(3):789-800. doi: 10.1007/s10549-013-2587-x. Epub 2013 Jun 19.

​

Comparative study analyzing survival and safety of bevacizumab/carboplatin/paclitaxel versus carboplatin/docetaxel in initial treatment of metastatic Her-2-negative breast cancer.

Kader YA, Spielmann M, El-Nahas T, Sakr A, Metwally H.

Breast Cancer (Dove Med Press). 2013 Jun 17;5:37-42. doi: 10.2147/BCTT.S44728. eCollection 2013.

​

Failure event types and prognostic factors after node-positive breast cancer in patients treated by adjuvant chemotherapy: impact on follow-up.

Filleron T, Kramar A, Dalenc F, Spielmann M, Fumoleau P, Kerbrat P, Martin AL, Roché H.

Bull Cancer. 2012 Jun;99(6):E64-74. doi: 10.1684/bdc.2012.1592.

​

Extended benefit from sequential administration of docetaxel after standard fluorouracil, epirubicin, and cyclophosphamide regimen for node-positive breast cancer: the 8-year follow-up results of the UNICANCER-PACS01 trial.

Coudert B, Asselain B, Campone M, Spielmann M, Machiels JP, Pénault-Llorca F, Serin D, Lévy C, Romieu G, Canon JL, Orfeuvre H, Piot G, Petit T, Jerusalem G, Audhuy B, Veyret C, Beauduin M, Eymard JC, Martin AL, Roché H; UNICANCER Breast Group.

Oncologist. 2012;17(7):900-9. doi: 10.1634/theoncologist.2011-0442. Epub 2012 May 18.

​

3D-conformal accelerated partial breast irradiation treatment planning: the value of surgical clips in the delineation of the lumpectomy cavity.

Dzhugashvili M, Tournay E, Pichenot C, Dunant A, Pessoa E, Khallel A, Gouy S, Uzan C, Garbay JR, Rimareix F, Spielmann M, Vielh P, Marsiglia H, Bourgier C.

Radiat Oncol. 2009 Dec 31;4:70. doi: 10.1186/1748-717X-4-70.

​

A multicenter randomized phase II study of sequential epirubicin/cyclophosphamide followed by docetaxel with or without celecoxib or trastuzumab according to HER2 status, as primary chemotherapy for localized invasive breast cancer patients.

Pierga JY, Delaloge S, Espié M, Brain E, Sigal-Zafrani B, Mathieu MC, Bertheau P, Guinebretière JM, Spielmann M, Savignoni A, Marty M.

Breast Cancer Res Treat. 2010 Jul;122(2):429-37. doi: 10.1007/s10549-010-0939-3. Epub 2010 May 18.

​

Efficacy of trastuzumab in routine clinical practice and after progression for metastatic breast cancer patients: the observational Hermine study.

Extra JM, Antoine EC, Vincent-Salomon A, Delozier T, Kerbrat P, Bethune-Volters A, Guastalla JP, Spielmann M, Mauriac L, Misset JL, Serin D, Campone M, Hebert C, Remblier C, Bergougnoux L, Campana F, Namer M.

Oncologist. 2010;15(8):799-809. doi: 10.1634/theoncologist.2009-0029. Epub 2010 Jul 29.

​

Feasibility of metronomic oral cyclophosphamide plus prednisolone in elderly patients with inoperable or metastatic soft tissue sarcoma.

Mir O, Domont J, Cioffi A, Bonvalot S, Boulet B, Le Pechoux C, Terrier P, Spielmann M, Le Cesne A.

Eur J Cancer. 2011 Mar;47(4):515-9. doi: 10.1016/j.ejca.2010.11.025. Epub 2011 Jan 19.

​

Exclusive alternating chemotherapy and radiotherapy in nonmetastatic inflammatory breast cancer: 20 years of follow-up.

Bourgier C, Pessoa EL, Dunant A, Heymann S, Spielmann M, Uzan C, Mathieu MC, Arriagada R, Marsiglia H.

Int J Radiat Oncol Biol Phys. 2012 Feb 1;82(2):690-5. doi: 10.1016/j.ijrobp.2010.11.040. Epub 2011 Jan 27.

​

[Node negative breast cancer. Beyond international consensus: a pragmatic approach].

Penault-Llorca F, Coeffic D, Delozier T, Dohollou N, Freyer G, Gligorov J, Hardy-Bessard AC, Jacot W, Misset JL, Nabholtz JM, Petit T, Spielmann M, Namer M.

Bull Cancer. 2011 Jul;98(7):807-25. doi: 10.1684/bdc.2011.1395. French.

​

Diagnosis and management of anaemia and iron deficiency in patients with haematological malignancies or solid tumours in France in 2009-2010: the AnemOnHe study.

Spielmann M, Luporsi E, Ray-Coquard I, de Botton S, Azria D, Lasocki S, Lafuma A, Mahi L, Deray G, Bugat R.

Eur J Cancer. 2012 Jan;48(1):101-7. doi: 10.1016/j.ejca.2011.09.011. Epub 2011 Oct 31.

​

Ki-67: level of evidence and methodological considerations for its role in the clinical management of breast cancer: analytical and critical review.

Luporsi E, André F, Spyratos F, Martin PM, Jacquemier J, Penault-Llorca F, Tubiana-Mathieu N, Sigal-Zafrani B, Arnould L, Gompel A, Egele C, Poulet B, Clough KB, Crouet H, Fourquet A, Lefranc JP, Mathelin C, Rouyer N, Serin D, Spielmann M, Haugh M, Chenard MP, Brain E, de Cremoux P, Bellocq JP.

Breast Cancer Res Treat. 2012 Apr;132(3):895-915. doi: 10.1007/s10549-011-1837-z. Epub 2011 Nov 3. Review.

​

Phase II trial of 3D-conformal accelerated partial breast irradiation: lessons learned from patients and physicians' evaluation.

Azoury F, Heymann S, Acevedo C, Spielmann M, Vielh P, Garbay JR, Taghian AG, Marsiglia H, Bourgier C.

Radiother Oncol. 2012 May;103(2):193-8. doi: 10.1016/j.radonc.2012.03.019. Epub 2012 Apr 20.

​

CXCR4 expression in early breast cancer and risk of distant recurrence.

Andre F, Xia W, Conforti R, Wei Y, Boulet T, Tomasic G, Spielmann M, Zoubir M, Berrada N, Arriagada R, Hortobagyi GN, Hung MC, Pusztai L, Delaloge S, Michiels S, Cristofanilli M.

Oncologist. 2009 Dec;14(12):1182-8. doi: 10.1634/theoncologist.2009-0161. Epub 2009 Nov 25.

​

Trastuzumab for patients with axillary-node-positive breast cancer: results of the FNCLCC-PACS 04 trial.

Spielmann M, Roché H, Delozier T, Canon JL, Romieu G, Bourgeois H, Extra JM, Serin D, Kerbrat P, Machiels JP, Lortholary A, Orfeuvre H, Campone M, Hardy-Bessard AC, Coudert B, Maerevoet M, Piot G, Kramar A, Martin AL, Penault-Llorca F.

J Clin Oncol. 2009 Dec 20;27(36):6129-34. doi: 10.1200/JCO.2009.23.0946. Epub 2009 Nov 16.

​

Prognostic role of pregnancy occurring before or after treatment of early breast cancer patients aged <35 years: a GET(N)A Working Group analysis.

Largillier R, Savignoni A, Gligorov J, Chollet P, Guilhaume MN, Spielmann M, Luporsi E, Asselain B, Coudert B, Namer M; GET(N)A Group.

Cancer. 2009 Nov 15;115(22):5155-65. doi: 10.1002/cncr.24608.

​

Exonic expression profiling of breast cancer and benign lesions: a retrospective analysis.

André F, Michiels S, Dessen P, Scott V, Suciu V, Uzan C, Lazar V, Lacroix L, Vassal G, Spielmann M, Vielh P, Delaloge S.

Lancet Oncol. 2009 Apr;10(4):381-90. doi: 10.1016/S1470-2045(09)70024-5. Epub 2009 Feb 25.

​

Physiopathology and management of osteonecrosis of the jaws related to bisphosphonate therapy for malignant bone lesions. A French expert panel analysis.

Tubiana-Hulin M, Spielmann M, Roux C, Campone M, Zelek L, Gligorov J, Samson J, Lesclous P, Laredo JD, Namer M.

Crit Rev Oncol Hematol. 2009 Jul;71(1):12-21. doi: 10.1016/j.critrevonc.2008.10.009. Epub 2008 Dec 12. Review.

​

[The use of deodorants/antiperspirants does not constitute a risk factor for breast cancer].

Namer M, Luporsi E, Gligorov J, Lokiec F, Spielmann M.

Bull Cancer. 2008 Sep;95(9):871-80. doi: 10.1684/bdc.2008.0679. Review. French.

​

Differential immunohistochemical and biological profile of squamous cell carcinoma of the breast.

Grenier J, Soria JC, Mathieu MC, Andre F, Abdelmoula S, Velasco V, Morat L, Besse B, Dunant A, Spielmann M, Delaloge S.

Anticancer Res. 2007 Jan-Feb;27(1B):547-55.

​

Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial.

Roché H, Fumoleau P, Spielmann M, Canon JL, Delozier T, Serin D, Symann M, Kerbrat P, Soulié P, Eichler F, Viens P, Monnier A, Vindevoghel A, Campone M, Goudier MJ, Bonneterre J, Ferrero JM, Martin AL, Genève J, Asselain B.

J Clin Oncol. 2006 Dec 20;24(36):5664-71. Epub 2006 Nov 20.

​

Dermal lymphatic emboli in inflammatory and noninflammatory breast cancer: a French-Tunisian joint study in 337 patients.

Lê MG, Arriagada R, Contesso G, Cammoun M, Pfeiffer F, Tabbane F, Bahi J, Dilaj M, Spielmann M, Travagli JP, Tursz T, Mourali N.

Clin Breast Cancer. 2005 Dec;6(5):439-45.

​

Nomograms to predict pathologic complete response and metastasis-free survival after preoperative chemotherapy for breast cancer.

Rouzier R, Pusztai L, Delaloge S, Gonzalez-Angulo AM, Andre F, Hess KR, Buzdar AU, Garbay JR, Spielmann M, Mathieu MC, Symmans WF, Wagner P, Atallah D, Valero V, Berry DA, Hortobagyi GN.

J Clin Oncol. 2005 Nov 20;23(33):8331-9.

​

Results of two randomized trials evaluating adjuvant anthracycline-based chemotherapy in 1146 patients with early breast cancer.

Arriagada R, Spielmann M, Koscielny S, Le Chevalier T, Delozier T, Rémé-Saumon M, Ducourtieux M, Tursz T, Hill C.

Acta Oncol. 2005;44(5):458-66.

​

The natural history of breast carcinoma in patients with 10 metastatic axillary lymph nodes before and after the advent of adjuvant therapy: a multiinstitutional retrospective study.

Montero AJ, Rouzier R, Lluch A, Theriault RL, Buzdar AU, Delaloge S, Bermejo B, Le M, Kau SW, Dunant A, Arriagada R, Spielmann M, Garcia-Conde J, Sahin AA, Singletary SE, Hortobagyi GN, Valero V.

Cancer. 2005 Jul 15;104(2):229-35.

​

Mitotic index and benefit of adjuvant anthracycline-based chemotherapy in patients with early breast cancer.

Andre F, Khalil A, Slimane K, Massard C, Mathieu MC, Vignot S, Assi H, Delaloge S, Spielmann M.

J Clin Oncol. 2005 May 1;23(13):2996-3000.

​

Breast-conserving surgery after neoadjuvant anthracycline-based chemotherapy for large breast tumors.

Rouzier R, Mathieu MC, Sideris L, Youmsi E, Rajan R, Garbay JR, André F, Marsiglia H, Spielmann M, Delaloge S.

Cancer. 2004 Sep 1;101(5):918-25.

​

Breast cancer with synchronous metastases: trends in survival during a 14-year period.

Andre F, Slimane K, Bachelot T, Dunant A, Namer M, Barrelier A, Kabbaj O, Spano JP, Marsiglia H, Rouzier R, Delaloge S, Spielmann M.

J Clin Oncol. 2004 Aug 15;22(16):3302-8.

​

Choroid metastases: clinical features and treatments in 123 patients.

d'Abbadie I, Arriagada R, Spielmann M, Lê MG.

Cancer. 2003 Sep 15;98(6):1232-8.

​

An attempt to clarify indications for hepatectomy for liver metastases from breast cancer.

Elias D, Maisonnette F, Druet-Cabanac M, Ouellet JF, Guinebretiere JM, Spielmann M, Delaloge S.

Am J Surg. 2003 Feb;185(2):158-64. Review.

​

Prognostic factors for death after an isolated local recurrence in patients with early-stage breast carcinoma.

Lê MG, Arriagada R, Spielmann M, Guinebretière JM, Rochard F.

Cancer. 2002 Jun 1;94(11):2813-20.

​

[Setting of a breast autologous microsurgical reconstructive surgery evolution in 20 years and review of 1138 cases].

Lantieri L, Hivelin M, Benjoar MD, Quilichini J, Hutzinger V, Marchac A, Lepage C.

Ann Chir Plast Esthet. 2015 Dec;60(6):484-9. doi: 10.1016/j.anplas.2015.06.009. Epub 2015 Aug 1. French.

​

The use of lipofilling to treat congenital hypoplastic breast anomalies: preliminary experiences.

Derder M, Whitaker IS, Boudana D, Marchac A, Hivelin M, Mattar N, Lepage C, Claude O, Benjoar MD, Bosc R, Lantieri L.

Ann Plast Surg. 2014 Oct;73(4):371-7. doi: 10.1097/SAP.0b013e31827fb3b7.

​

Lessons learned from simultaneous face and bilateral hand allotransplantation.

Carty MJ, Hivelin M, Dumontier C, Talbot SG, Benjoar MD, Pribaz JJ, Lantieri L, Pomahac B.

Plast Reconstr Surg. 2013 Aug;132(2):423-32. doi: 10.1097/PRS.0b013e318295883d.

​

Restoration of the donor after face graft procurement for allotransplantation: report on the technique and outcomes of seven cases.

Quilichini J, Hivelin M, Benjoar MD, Bosc R, Meningaud JP, Lantieri L.

Plast Reconstr Surg. 2012 May;129(5):1105-11. doi: 10.1097/PRS.0b013e31824a2bf8.

​

Face transplantation program in France: a cost analysis of five patients.

Rüegg EM, Hivelin M, Hemery F, Maciver C, Benjoar MD, Meningaud JP, Lantieri L.

Transplantation. 2012 Jun 15;93(11):1166-72. doi: 10.1097/TP.0b013e31824e75fa.

​

Split-thickness skin graft harvested from the scalp for the coverage of extensive temple or forehead defects in elderly patients.

Quilichini J, Benjoar MD, Hivelin M, Lantieri L.

Arch Facial Plast Surg. 2012 Mar-Apr;14(2):137-9. doi: 10.1001/archfacial.2011.1345.

​

Semi-free radial forearm flap for head and neck reconstruction in vessel-depleted neck after radiotherapy or radical neck dissection.

Quilichini J, Benjoar MD, Hivelin M, Brugel L, Lantieri L.

Microsurgery. 2012 May;32(4):269-74. doi: 10.1002/micr.21945. Epub 2012 Feb 27.

 

Septocutaneous gluteal artery perforator flap in lateral decubitus position for breast reconstruction.

Quilichini J, Hivelin M, Matar N, Benjoar MD, Lantieri L.

Plast Reconstr Surg. 2012 Feb;129(2):385e-386e. doi: 10.1097/PRS.0b013e31823af0a9. No abstract available.

 

[A cost analysis of DIEP flap in breast reconstruction].

Marchac A, Bosc R, Benjoar MD, Hivelin M, Lepage C, Lantieri L.

Ann Chir Plast Esthet. 2011 Aug;56(4):275-9. doi: 10.1016/j.anplas.2011.06.001. Epub 2011 Jul 22. French.

​

Management of chest wall reconstruction after resection for cancer: a retrospective study of 22 consecutive patients.

Bosc R, Lepage C, Hamou C, Matar N, Benjoar MD, Hivelin M, Lantieri L.

Ann Plast Surg. 2011 Sep;67(3):263-8. doi: 10.1097/SAP.0b013e3181f9b292.

​

Clinical images: Necrosis at the tip of the nose in an 83-year-old man.

Hotz C, Valeyrie-Allanore L, Benjoar MD, Ortonne N, Vitte E, Bouvresse S, Brun-Buisson C, Wolkenstein P, Chosidow O.

Arthritis Rheum. 2011 Jun;63(6):1762. doi: 10.1002/art.30343. No abstract available.

​

Feasibility, reproducibility, risks and benefits of face transplantation: a prospective study of outcomes.

Lantieri L, Hivelin M, Audard V, Benjoar MD, Meningaud JP, Bellivier F, Ortonne N, Lefaucheur JP, Gilton A, Suberbielle C, Marty J, Lang P, Grimbert P.

Am J Transplant. 2011 Feb;11(2):367-78. doi: 10.1111/j.1600-6143.2010.03406.x.

The procurement of allotransplants for ballistic trauma: a preclinical study and a report of two clinical cases.

Meningaud JP, Hivelin M, Benjoar MD, Toure G, Hermeziu O, Lantieri L.

Plast Reconstr Surg. 2011 May;127(5):1892-900. doi: 10.1097/PRS.0b013e31820e915a.

 

[Breast reconstruction with superior gluteal artery perforator (SGAP) flap without intraoperative setup change. About eight cases].

Matar N, Quilichini J, Bosc R, Benjoar MD, Lantieri L.

Ann Chir Plast Esthet. 2010 Dec;55(6):539-46. doi: 10.1016/j.anplas.2010.09.010. Epub 2010 Oct 16. French.

​

[Preoperative angiographic CT-scan for perforator flap transfer. Clinical applications in an emergency unit of reconstructive surgery: four clinical cases].

Bosc R, Hivelin M, Benjoar MD, Pigneur F, Lantieri L.

Ann Chir Plast Esthet. 2010 Aug;55(4):307-12. doi: 10.1016/j.anplas.2009.11.006. Epub 2010 Jun 17. French.

​

Procurement of total human face graft for allotransplantation: a preclinical study and the first clinical case.

Meningaud JP, Benjoar MD, Hivelin M, Hermeziu O, Toure G, Lantieri L.

Plast Reconstr Surg. 2010 Oct;126(4):1181-90. doi: 10.1097/PRS.0b013e3181ec2089.

​

[Complications of injections of hypoosmotic solutes in an underage patient].

Benjoar MD, Lepage C, Hivelin M, Lantieri L.

Ann Chir Plast Esthet. 2009 Apr;54(2):161-4. doi: 10.1016/j.anplas.2008.09.003. Epub 2009 Feb 4. French.

 

Repair of the lower and middle parts of the face by composite tissue allotransplantation in a patient with massive plexiform neurofibroma: a 1-year follow-up study.

Lantieri L, Meningaud JP, Grimbert P, Bellivier F, Lefaucheur JP, Ortonne N, Benjoar MD, Lang P, Wolkenstein P.

Lancet. 2008 Aug 23;372(9639):639-45. doi: 10.1016/S0140-6736(08)61277-5.

​

Clinical use of ferric carboxymaltose in patients with solid tumours or haematological malignancies in France.

Toledano A, Luporsi E, Morere JF, Scotté F, Laribi K, Barrière J, Huot-Marchand P, Duvillié L, Concas VH, Bugat R.

Support Care Cancer. 2016 Jan;24(1):67-75. doi: 10.1007/s00520-015-2728-3. Epub 2015 Apr 29.

​

[First case of complete genomic sequencing in prostate cancer].

Pene F, Toledano A, Laabidi M.

Prog Urol. 2014 Dec;24(16):1041-2. doi: 10.1016/j.purol.2014.09.036. Epub 2014 Oct 5. French. No abstract available.

​

[Impact of late treatment-related radiotherapy toxicity, depression, and anxiety on quality of life in long-term breast cancer survivors].

Brunault P, Toledano A, Aguerre C, Suzanne I, Garaud P, Trzepidur-Edom M, Calais G, Camus V.

Bull Cancer. 2012 May;99(5):589-98. doi: 10.1684/bdc.2012.1569. French.

​

Factors of late radiosensitivity of normal tissues].

Azria D, Pointreau Y, Toledano A, Ozsahin M.

Cancer Radiother. 2010 Jul;14(4-5):250-4. doi: 10.1016/j.canrad.2010.04.002. Epub 2010 Jul 2. French.

​

[Elevation of PSA after prostate radiotherapy: rebound or biochemical recurrence?].

Toledano A, Chiche R, Lamallem H, Kanoui A, Beley S, Thibault F, Sèbe P.

Prog Urol. 2008 Oct;18(9):557-61. doi: 10.1016/j.purol.2008.06.001. Epub 2008 Jul 26. Review. French.

​

[Ductal carcinoma in situ: role of the boost].

Azria D, Auvray H, Barillot I, Baumann P, Benyoucef A, Bons-Rosset F, Bontemps P, Bourgier C, Breton-Callu C, Cowen D, Cretin J, Delalande B, Denis F, Ellis S, Gaci Z, Hannoun-Lévy JM, Hasbini A, Hennequin C, Lagrange JL, Lartigau E, Latorzeff I, Le Blanc-Onfroy M, Lecouillard I, Lemanski C, Levy C, Maingon P, Marchal C, Monnier A, Pradier O, Racadot S, Romestaing P, Serin D, Simon JM, Teyssier E, Tallet A, Tolédano A, Belkacémi Y.

Cancer Radiother. 2008 Nov;12(6-7):571-6. doi: 10.1016/j.canrad.2008.07.005. Epub 2008 Aug 13. Review. French.

​

[Progress in radiation therapy and integration in Tenon hospital (AP-HP) of new advances in routine practices of radiotherapy for non-small-cell lung cancer].

Touboul E, Huguet F, Foulquier JN, Toledano A, Deluen F, Rahmoun M, Cojocariu OM, Le Nagat S.

Rev Pneumol Clin. 2007 Jun;63(3):211-22. French.

​

Phase III trial of concurrent or sequential adjuvant chemoradiotherapy after conservative surgery for early-stage breast cancer: final results of the ARCOSEIN trial.

Toledano A, Azria D, Garaud P, Fourquet A, Serin D, Bosset JF, Miny-Buffet J, Favre A, Le Floch O, Calais G.

J Clin Oncol. 2007 Feb 1;25(4):405-10. Erratum in: J Clin Oncol. 2007 Jun 1;25(16):2334.

​

[PSA bounce after permanent implant prostate brachytherapy may mimic a biochemical failure].

Toledano A, Chauveinc L, Flam T, Thiounn N, Solignac S, Timbert M, Rosenwald JC, Cosset JM.

Cancer Radiother. 2007 May;11(3):105-10. Epub 2006 Dec 8. French.

​

PSA bounce after permanent implant prostate brachytherapy may mimic a biochemical failure: a study of 295 patients with a minimum 3-year followup.

Toledano A, Chauveinc L, Flam T, Thiounn N, Solignac S, Timbert M, Rosenwald JC, Cosset JM.

Brachytherapy. 2006 Apr-Jun;5(2):122-6.

​

[Concurrent administration of adjuvant chemotherapy and radiotherapy after breast-conservative surgery enhances late toxicities].

Toledano A, Garaud P, Serin D, Fourquet A, Bosset JF, Miny-Buffet J, Favre A, Azria D, Body G, Le Floch O, Calais G.

Cancer Radiother. 2006 Jun;10(4):158-67. Epub 2006 Apr 24. French.

​

Concurrent administration of adjuvant chemotherapy and radiotherapy after breast-conserving surgery enhances late toxicities: long-term results of the ARCOSEIN multicenter randomized study.

Toledano A, Garaud P, Serin D, Fourquet A, Bosset JF, Breteau N, Body G, Azria D, Le Floch O, Calais G.

Int J Radiat Oncol Biol Phys. 2006 Jun 1;65(2):324-32. Epub 2006 Mar 20.

​

​

​

​

​

​

Proliferation and ovarian hormone signaling are impaired in normal breast tissues from women with BRCA1 mutations: benefit of a progesterone receptor modulator treatment as a breast cancer preventive strategy in women with inherited BRCA1 mutations.

Communal L, Vilasco M, Hugon-Rodin J, Courtin A, Mourra N, Lahlou N, Le Guillou M, Perrault de Jotemps M, Chauvet MP, Chaouat M, Pujol P, Feunteun J, Delaloge S, Forgez P, Gompel A.

Oncotarget. 2016 May 26. doi: 10.18632/oncotarget.9638. [Epub ahead of print]

​

Contribution of BRCA1 and BRCA2 Germline Mutations to Early Algerian Breast Cancer.

Henouda S, Bensalem A, Reggad R, Serrar N, Rouabah L, Pujol P.

Dis Markers. 2016;2016:7869095. doi: 10.1155/2016/7869095. Epub 2016 Feb 22.

​

Correction: Preferential Allele Expression Analysis Identifies Shared Germline and Somatic Driver Genes in Advanced Ovarian Cancer.

Halabi NM, Martinez A, Al-Farsi H, Mery E, Puydenus L, Pujol P, Khalak HG, McLurcan C, Ferron G, Querleu D, Al-Azwani I, Al-Dous E, Mohamoud YA, Malek JA, Rafii A.

PLoS Genet. 2016 Feb 18;12(2):e1005892. doi: 10.1371/journal.pgen.1005892. eCollection 2016 Feb. No abstract available.

​

GENESIS: a French national resource to study the missing heritability of breast cancer.

Sinilnikova OM, Dondon MG, Eon-Marchais S, Damiola F, Barjhoux L, Marcou M, Verny-Pierre C, Sornin V, Toulemonde L, Beauvallet J, Le Gal D, Mebirouk N, Belotti M, Caron O, Gauthier-Villars M, Coupier I, Buecher B, Lortholary A, Dugast C, Gesta P, Fricker JP, Noguès C, Faivre L, Luporsi E, Berthet P, Delnatte C, Bonadona V, Maugard CM, Pujol P, Lasset C, Longy M, Bignon YJ, Adenis C, Venat-Bouvet L, Demange L, Dreyfus H, Frenay M, Gladieff L, Mortemousque I, Audebert-Bellanger S, Soubrier F, Giraud S, Lejeune-Dumoulin S, Chevrier A, Limacher JM, Chiesa J, Fajac A, Floquet A, Eisinger F, Tinat J, Colas C, Fert-Ferrer S, Penet C, Frebourg T, Collonge-Rame MA, Barouk-Simonet E, Layet V, Leroux D, Cohen-Haguenauer O, Prieur F, Mouret-Fourme E, Cornélis F, Jonveaux P, Bera O, Cavaciuti E, Tardivon A, Lesueur F, Mazoyer S, Stoppa-Lyonnet D, Andrieu N.

BMC Cancer. 2016 Jan 12;16:13. doi: 10.1186/s12885-015-2028-9.

​

Preferential Allele Expression Analysis Identifies Shared Germline and Somatic Driver Genes in Advanced Ovarian Cancer.

Halabi NM, Martinez A, Al-Farsi H, Mery E, Puydenus L, Pujol P, Khalak HG, McLurcan C, Ferron G, Querleu D, Al-Azwani I, Al-Dous E, Mohamoud YA, Malek JA, Rafii A.

PLoS Genet. 2016 Jan 6;12(1):e1005755. doi: 10.1371/journal.pgen.1005755. eCollection 2016 Jan. Erratum in: PLoS Genet. 2016 Feb;12(2):e1005892.

​

Mutation analysis of PALB2 gene in French breast cancer families.

Damiola F, Schultz I, Barjhoux L, Sornin V, Dondon MG, Eon-Marchais S, Marcou M; GENESIS Study Investigators, Caron O, Gauthier-Villars M, de Pauw A, Luporsi E, Berthet P, Delnatte C, Bonadona V, Maugard C, Pujol P, Lasset C, Longy M, Bignon YJ, Fricker JP, Andrieu N, Sinilnikova OM, Stoppa-Lyonnet D, Mazoyer S, Muller D.

Breast Cancer Res Treat. 2015 Dec;154(3):463-71. doi: 10.1007/s10549-015-3625-7. Epub 2015 Nov 12.

​

Autologous platelet concentrate in surgery for macular detachment associated with congenital optic disc pit.

Nadal J, Figueroa MS, Carreras E, Pujol P, Canut MI, Barraquer RI.

Clin Ophthalmol. 2015 Oct 22;9:1965-71. doi: 10.2147/OPTH.S81976. eCollection 2015.

​

Clinical relevance of 8q23, 15q13 and 18q21 SNP genotyping to evaluate colorectal cancer risk.

Baert-Desurmont S, Charbonnier F, Houivet E, Ippolito L, Mauillon J, Bougeard M, Abadie C, Malka D, Duffour J, Desseigne F, Colas C, Pujol P, Lejeune S, Dugast C, Buecher B, Faivre L, Leroux D, Gesta P, Coupier I, Guimbaud R, Berthet P, Manouvrier S, Cauchin E, Prieur F, Laurent-Puig P, Lebrun M, Jonveaux P, Chiesa J, Caron O, Morin-Meschin ME, Polycarpe-Osaer F, Giraud S, Zaanan A, Bonnet D, Mansuy L, Bonadona V, El Chehadeh S, Duhoux F, Gauthier-Villars M, Saurin JC, Collonge-Rame MA, Brugières L, Wang Q, Bressac-de Paillerets B, Rey JM, Toulas C, Buisine MP, Bronner M, Sokolowska J, Hardouin A, Cailleux AF, Sebaoui H, Blot J, Tinat J, Benichou J, Frebourg T.

Eur J Hum Genet. 2016 Jan;24(1):99-105. doi: 10.1038/ejhg.2015.72. Epub 2015 Apr 15.

​

Assessing associations between the AURKA-HMMR-TPX2-TUBG1 functional module and breast cancer risk in BRCA1/2 mutation carriers.

Blanco I, Kuchenbaecker K, Cuadras D, Wang X, Barrowdale D, de Garibay GR, Librado P, Sánchez-Gracia A, Rozas J, Bonifaci N, McGuffog L, Pankratz VS, Islam A, Mateo F, Berenguer A, Petit A, Català I, Brunet J, Feliubadaló L, Tornero E, Benítez J, Osorio A, Ramón y Cajal T, Nevanlinna H, Aittomäki K, Arun BK, Toland AE, Karlan BY, Walsh C, Lester J, Greene MH, Mai PL, Nussbaum RL, Andrulis IL, Domchek SM, Nathanson KL, Rebbeck TR, Barkardottir RB, Jakubowska A, Lubinski J, Durda K, Jaworska-Bieniek K, Claes K, Van Maerken T, Díez O, Hansen TV, Jønson L, Gerdes AM, Ejlertsen B, de la Hoya M, Caldés T, Dunning AM, Oliver C, Fineberg E, Cook M, Peock S, McCann E, Murray A, Jacobs C, Pichert G, Lalloo F, Chu C, Dorkins H, Paterson J, Ong KR, Teixeira MR; Teixeira, Hogervorst FB, van der Hout AH, Seynaeve C, van der Luijt RB, Ligtenberg MJ, Devilee P, Wijnen JT, Rookus MA, Meijers-Heijboer HE, Blok MJ, van den Ouweland AM, Aalfs CM, Rodriguez GC, Phillips KA, Piedmonte M, Nerenstone SR, Bae-Jump VL, O'Malley DM, Ratner ES, Schmutzler RK, Wappenschmidt B, Rhiem K, Engel C, Meindl A, Ditsch N, Arnold N, Plendl HJ, Niederacher D, Sutter C, Wang-Gohrke S, Steinemann D, Preisler-Adams S, Kast K, Varon-Mateeva R, Gehrig A, Bojesen A, Pedersen IS, Sunde L, Jensen UB, Thomassen M, Kruse TA, Foretova L, Peterlongo P, Bernard L, Peissel B, Scuvera G, Manoukian S, Radice P, Ottini L, Montagna M, Agata S, Maugard C, Simard J, Soucy P, Berger A, Fink-Retter A, Singer CF, Rappaport C, Geschwantler-Kaulich D, Tea MK, Pfeiler G; BCFR, John EM, Miron A, Neuhausen SL, Terry MB, Chung WK, Daly MB, Goldgar DE, Janavicius R, Dorfling CM, van Rensburg EJ, Fostira F, Konstantopoulou I, Garber J, Godwin AK, Olah E, Narod SA, Rennert G, Paluch SS, Laitman Y, Friedman E; SWE-BRCA, Liljegren A, Rantala J, Stenmark-Askmalm M, Loman N, Imyanitov EN, Hamann U; kConFab Investigators, Spurdle AB, Healey S, Weitzel JN, Herzog J, Margileth D, Gorrini C, Esteller M, Gómez A, Sayols S, Vidal E, Heyn H; GEMO, Stoppa-Lyonnet D, Léoné M, Barjhoux L, Fassy-Colcombet M, de Pauw A, Lasset C, Ferrer SF, Castera L, Berthet P, Cornelis F, Bignon YJ, Damiola F, Mazoyer S, Sinilnikova OM, Maxwell CA, Vijai J, Robson M, Kauff N, Corines MJ, Villano D, Cunningham J, Lee A, Lindor N, Lázaro C, Easton DF, Offit K, Chenevix-Trench G, Couch FJ, Antoniou AC, Pujana MA.

PLoS One. 2015 Apr 1;10(4):e0120020. doi: 10.1371/journal.pone.0120020. eCollection 2015.

​

Breast Cancer Risk Associated with Estrogen Exposure and Truncating Mutation Location in BRCA1/2 Carriers.

Lecarpentier J, Noguès C, Mouret-Fourme E, Buecher B, Gauthier-Villars M, Stoppa-Lyonnet D, Bonadona V, Fricker JP, Berthet P, Caron O, Coupier I, Pujol P, Faivre L, Gesta P, Eisinger F, Mari V, Gladieff L, Lortholary A, Luporsi E, Leroux D, Venat-Bouvet L, Maugard CM, Colas C, Tinat J, Lasset C, Andrieu N; GENEPSO.

Cancer Epidemiol Biomarkers Prev. 2015 Apr;24(4):698-707. doi: 10.1158/1055-9965.EPI-14-0884. Epub 2015 Jan 22.

​

Candidate genetic modifiers for breast and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers.

Peterlongo P, Chang-Claude J, Moysich KB, Rudolph A, Schmutzler RK, Simard J, Soucy P, Eeles RA, Easton DF, Hamann U, Wilkening S, Chen B, Rookus MA, Schmidt MK, van der Baan FH, Spurdle AB, Walker LC, Lose F, Maia AT, Montagna M, Matricardi L, Lubinski J, Jakubowska A, Gómez Garcia EB, Olopade OI, Nussbaum RL, Nathanson KL, Domchek SM, Rebbeck TR, Arun BK, Karlan BY, Orsulic S, Lester J, Chung WK, Miron A, Southey MC, Goldgar DE, Buys SS, Janavicius R, Dorfling CM, van Rensburg EJ, Ding YC, Neuhausen SL, Hansen TV, Gerdes AM, Ejlertsen B, Jønson L, Osorio A, Martínez-Bouzas C, Benitez J, Conway EE, Blazer KR, Weitzel JN, Manoukian S, Peissel B, Zaffaroni D, Scuvera G, Barile M, Ficarazzi F, Mariette F, Fortuzzi S, Viel A, Giannini G, Papi L, Martayan A, Tibiletti MG, Radice P, Vratimos A, Fostira F, Garber JE, Donaldson A, Brewer C, Foo C, Evans DG, Frost D, Eccles D, Brady A, Cook J, Tischkowitz M, Adlard J, Barwell J, Walker L, Izatt L, Side LE, Kennedy MJ, Rogers MT, Porteous ME, Morrison PJ, Platte R, Davidson R, Hodgson SV, Ellis S, Cole T; EMBRACE, Godwin AK, Claes K, Van Maerken T, Meindl A, Gehrig A, Sutter C, Engel C, Niederacher D, Steinemann D, Plendl H, Kast K, Rhiem K, Ditsch N, Arnold N, Varon-Mateeva R, Wappenschmidt B, Wang-Gohrke S, Bressac-de Paillerets B, Buecher B, Delnatte C, Houdayer C, Stoppa-Lyonnet D, Damiola F, Coupier I, Barjhoux L, Venat-Bouvet L, Golmard L, Boutry-Kryza N, Sinilnikova OM, Caron O, Pujol P, Mazoyer S, Belotti M; GEMO Study Collaborators, Piedmonte M, Friedlander ML, Rodriguez GC, Copeland LJ, de la Hoya M, Segura PP, Nevanlinna H, Aittomäki K, van Os TA, Meijers-Heijboer HE, van der Hout AH, Vreeswijk MP, Hoogerbrugge N, Ausems MG, van Doorn HC, Collée JM; HEBON, Olah E, Diez O, Blanco I, Lazaro C, Brunet J, Feliubadalo L, Cybulski C, Gronwald J, Durda K, Jaworska-Bieniek K, Sukiennicki G, Arason A, Chiquette J, Teixeira MR, Olswold C, Couch FJ, Lindor NM, Wang X, Szabo CI, Offit K, Corines M, Jacobs L, Robson ME, Zhang L, Joseph V, Berger A, Singer CF, Rappaport C, Kaulich DG, Pfeiler G, Tea MK, Phelan CM, Greene MH, Mai PL, Rennert G, Mulligan AM, Glendon G, Tchatchou S, Andrulis IL, Toland AE, Bojesen A, Pedersen IS, Thomassen M, Jensen UB, Laitman Y, Rantala J, von Wachenfeldt A, Ehrencrona H, Askmalm MS, Borg Å, Kuchenbaecker KB, McGuffog L, Barrowdale D, Healey S, Lee A, Pharoah PD, Chenevix-Trench G; KConFab Investigators, Antoniou AC, Friedman E.

Cancer Epidemiol Biomarkers Prev. 2015 Jan;24(1):308-16. doi: 10.1158/1055-9965.EPI-14-0532. Epub 2014 Oct 21.

​

Quality of life in MAP.3 (Mammary Prevention 3): a randomized, placebo-controlled trial evaluating exemestane for prevention of breast cancer.

Maunsell E, Goss PE, Chlebowski RT, Ingle JN, Alés-Martínez JE, Sarto GE, Fabian CJ, Pujol P, Ruiz A, Cooke AL, Hendrix S, Thayer DW, Rowland KM, Dubé P, Spadafora S, Pruthi S, Lickley L, Ellard SL, Cheung AM, Wactawski-Wende J, Gelmon KA, Johnston D, Hiltz A, Brundage M, Pater JL, Tu D, Richardson H.

J Clin Oncol. 2014 May 10;32(14):1427-36. doi: 10.1200/JCO.2013.51.2483. Epub 2014 Apr 7.

​

Associations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in BRCA1 and BRCA2 mutation carriers.

Kuchenbaecker KB, Neuhausen SL, Robson M, Barrowdale D, McGuffog L, Mulligan AM, Andrulis IL, Spurdle AB, Schmidt MK, Schmutzler RK, Engel C, Wappenschmidt B, Nevanlinna H, Thomassen M, Southey M, Radice P, Ramus SJ, Domchek SM, Nathanson KL, Lee A, Healey S, Nussbaum RL, Rebbeck TR, Arun BK, James P, Karlan BY, Lester J, Cass I; Breast Cancer Family Registry, Terry MB, Daly MB, Goldgar DE, Buys SS, Janavicius R, Tihomirova L, Tung N, Dorfling CM, van Rensburg EJ, Steele L, v O Hansen T, Ejlertsen B, Gerdes AM, Nielsen FC, Dennis J, Cunningham J, Hart S, Slager S, Osorio A, Benitez J, Duran M, Weitzel JN, Tafur I, Hander M, Peterlongo P, Manoukian S, Peissel B, Roversi G, Scuvera G, Bonanni B, Mariani P, Volorio S, Dolcetti R, Varesco L, Papi L, Tibiletti MG, Giannini G, Fostira F, Konstantopoulou I, Garber J, Hamann U, Donaldson A, Brewer C, Foo C, Evans DG, Frost D, Eccles D; EMBRACE Study, Douglas F, Brady A, Cook J, Tischkowitz M, Adlard J, Barwell J, Ong KR, Walker L, Izatt L, Side LE, Kennedy MJ, Rogers MT, Porteous ME, Morrison PJ, Platte R, Eeles R, Davidson R, Hodgson S, Ellis S, Godwin AK, Rhiem K, Meindl A, Ditsch N, Arnold N, Plendl H, Niederacher D, Sutter C, Steinemann D, Bogdanova-Markov N, Kast K, Varon-Mateeva R, Wang-Gohrke S, Gehrig A, Markiefka B, Buecher B, Lefol C, Stoppa-Lyonnet D, Rouleau E, Prieur F, Damiola F; GEMO Study Collaborators, Barjhoux L, Faivre L, Longy M, Sevenet N, Sinilnikova OM, Mazoyer S, Bonadona V, Caux-Moncoutier V, Isaacs C, Van Maerken T, Claes K, Piedmonte M, Andrews L, Hays J, Rodriguez GC, Caldes T, de la Hoya M, Khan S, Hogervorst FB, Aalfs CM, de Lange JL, Meijers-Heijboer HE, van der Hout AH, Wijnen JT, van Roozendaal KE, Mensenkamp AR, van den Ouweland AM, van Deurzen CH, van der Luijt RB; HEBON, Olah E, Diez O, Lazaro C, Blanco I, Teulé A, Menendez M, Jakubowska A, Lubinski J, Cybulski C, Gronwald J, Jaworska-Bieniek K, Durda K, Arason A, Maugard C, Soucy P, Montagna M, Agata S, Teixeira MR; KConFab Investigators, Olswold C, Lindor N, Pankratz VS, Hallberg E, Wang X, Szabo CI, Vijai J, Jacobs L, Corines M, Lincoln A, Berger A, Fink-Retter A, Singer CF, Rappaport C, Kaulich DG, Pfeiler G, Tea MK, Phelan CM, Mai PL, Greene MH, Rennert G, Imyanitov EN, Glendon G, Toland AE, Bojesen A, Pedersen IS, Jensen UB, Caligo MA, Friedman E, Berger R, Laitman Y, Rantala J, Arver B, Loman N, Borg A, Ehrencrona H, Olopade OI, Simard J, Easton DF, Chenevix-Trench G, Offit K, Couch FJ, Antoniou AC; CIMBA.

Breast Cancer Res. 2014 Dec 31;16(6):3416. doi: 10.1186/s13058-014-0492-9.

​

Lack of referral for genetic counseling and testing in BRCA1/2 and Lynch syndromes: a nationwide study based on 240,134 consultations and 134,652 genetic tests.

Pujol P, Lyonnet DS, Frebourg T, Blin J, Picot MC, Lasset C, Dugast C, Berthet P, de Paillerets BB, Sobol H, Grandjouan S, Soubrier F, Buecher B, Guimbaud R, Lidereau R, Jonveaux P, Houdayer C, Giraud S, Olschwang S, Nogue E, Galibert V, Bara C, Nowak F, Khayat D, Nogues C.

Breast Cancer Res Treat. 2013 Aug;141(1):135-44. doi: 10.1007/s10549-013-2669-9. Epub 2013 Aug 24.

​

Tamoxifen and risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers.

Phillips KA, Milne RL, Rookus MA, Daly MB, Antoniou AC, Peock S, Frost D, Easton DF, Ellis S, Friedlander ML, Buys SS, Andrieu N, Noguès C, Stoppa-Lyonnet D, Bonadona V, Pujol P, McLachlan SA, John EM, Hooning MJ, Seynaeve C, Tollenaar RA, Goldgar DE, Terry MB, Caldes T, Weideman PC, Andrulis IL, Singer CF, Birch K, Simard J, Southey MC, Olsson HL, Jakubowska A, Olah E, Gerdes AM, Foretova L, Hopper JL.

J Clin Oncol. 2013 Sep 1;31(25):3091-9. doi: 10.1200/JCO.2012.47.8313. Epub 2013 Aug 5.

​

Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk.

Couch FJ, Wang X, McGuffog L, Lee A, Olswold C, Kuchenbaecker KB, Soucy P, Fredericksen Z, Barrowdale D, Dennis J, Gaudet MM, Dicks E, Kosel M, Healey S, Sinilnikova OM, Lee A, Bacot F, Vincent D, Hogervorst FB, Peock S, Stoppa-Lyonnet D, Jakubowska A; kConFab Investigators, Radice P, Schmutzler RK; SWE-BRCA, Domchek SM, Piedmonte M, Singer CF, Friedman E, Thomassen M; Ontario Cancer Genetics Network, Hansen TV, Neuhausen SL, Szabo CI, Blanco I, Greene MH, Karlan BY, Garber J, Phelan CM, Weitzel JN, Montagna M, Olah E, Andrulis IL, Godwin AK, Yannoukakos D, Goldgar DE, Caldes T, Nevanlinna H, Osorio A, Terry MB, Daly MB, van Rensburg EJ, Hamann U, Ramus SJ, Toland AE, Caligo MA, Olopade OI, Tung N, Claes K, Beattie MS, Southey MC, Imyanitov EN, Tischkowitz M, Janavicius R, John EM, Kwong A, Diez O, Balmaña J, Barkardottir RB, Arun BK, Rennert G, Teo SH, Ganz PA, Campbell I, van der Hout AH, van Deurzen CH, Seynaeve C, Gómez Garcia EB, van Leeuwen FE, Meijers-Heijboer HE, Gille JJ, Ausems MG, Blok MJ, Ligtenberg MJ, Rookus MA, Devilee P, Verhoef S, van Os TA, Wijnen JT; HEBON; EMBRACE, Frost D, Ellis S, Fineberg E, Platte R, Evans DG, Izatt L, Eeles RA, Adlard J, Eccles DM, Cook J, Brewer C, Douglas F, Hodgson S, Morrison PJ, Side LE, Donaldson A, Houghton C, Rogers MT, Dorkins H, Eason J, Gregory H, McCann E, Murray A, Calender A, Hardouin A, Berthet P, Delnatte C, Nogues C, Lasset C, Houdayer C, Leroux D, Rouleau E, Prieur F, Damiola F, Sobol H, Coupier I, Venat-Bouvet L, Castera L, Gauthier-Villars M, Léoné M, Pujol P, Mazoyer S, Bignon YJ; GEMO Study Collaborators, Złowocka-Perłowska E, Gronwald J, Lubinski J, Durda K, Jaworska K, Huzarski T, Spurdle AB, Viel A, Peissel B, Bonanni B, Melloni G, Ottini L, Papi L, Varesco L, Tibiletti MG, Peterlongo P, Volorio S, Manoukian S, Pensotti V, Arnold N, Engel C, Deissler H, Gadzicki D, Gehrig A, Kast K, Rhiem K, Meindl A, Niederacher D, Ditsch N, Plendl H, Preisler-Adams S, Engert S, Sutter C, Varon-Mateeva R, Wappenschmidt B, Weber BH, Arver B, Stenmark-Askmalm M, Loman N, Rosenquist R, Einbeigi Z, Nathanson KL, Rebbeck TR, Blank SV, Cohn DE, Rodriguez GC, Small L, Friedlander M, Bae-Jump VL, Fink-Retter A, Rappaport C, Gschwantler-Kaulich D, Pfeiler G, Tea MK, Lindor NM, Kaufman B, Shimon Paluch S, Laitman Y, Skytte AB, Gerdes AM, Pedersen IS, Moeller ST, Kruse TA, Jensen UB, Vijai J, Sarrel K, Robson M, Kauff N, Mulligan AM, Glendon G, Ozcelik H, Ejlertsen B, Nielsen FC, Jønson L, Andersen MK, Ding YC, Steele L, Foretova L, Teulé A, Lazaro C, Brunet J, Pujana MA, Mai PL, Loud JT, Walsh C, Lester J, Orsulic S, Narod SA, Herzog J, Sand SR, Tognazzo S, Agata S, Vaszko T, Weaver J, Stavropoulou AV, Buys SS, Romero A, de la Hoya M, Aittomäki K, Muranen TA, Duran M, Chung WK, Lasa A, Dorfling CM, Miron A; BCFR, Benitez J, Senter L, Huo D, Chan SB, Sokolenko AP, Chiquette J, Tihomirova L, Friebel TM, Agnarsson BA, Lu KH, Lejbkowicz F, James PA, Hall P, Dunning AM, Tessier D, Cunningham J, Slager SL, Wang C, Hart S, Stevens K, Simard J, Pastinen T, Pankratz VS, Offit K, Easton DF, Chenevix-Trench G, Antoniou AC; CIMBA.

PLoS Genet. 2013;9(3):e1003212. doi: 10.1371/journal.pgen.1003212. Epub 2013 Mar 27.

​

Variation in breast cancer risk associated with factors related to pregnancies according to truncating mutation location, in the French National BRCA1 and BRCA2 mutations carrier cohort (GENEPSO).

Lecarpentier J, Noguès C, Mouret-Fourme E, Gauthier-Villars M, Lasset C, Fricker JP, Caron O, Stoppa-Lyonnet D, Berthet P, Faivre L, Bonadona V, Buecher B, Coupier I, Gladieff L, Gesta P, Eisinger F, Frénay M, Luporsi E, Lortholary A, Colas C, Dugast C, Longy M, Pujol P, Tinat J; GENEPSO, Lidereau R, Andrieu N.

Breast Cancer Res. 2012 Jul 3;14(4):R99. doi: 10.1186/bcr3218.

​

Familial melanoma: clinical factors associated with germline CDKN2A mutations according to the number of patients affected by melanoma in a family.

Maubec E, Chaudru V, Mohamdi H, Blondel C, Margaritte-Jeannin P, Forget S, Corda E, Boitier F, Dalle S, Vabres P, Perrot JL, Lyonnet DS, Zattara H, Mansard S, Grange F, Leccia MT, Vincent-Fetita L, Martin L, Crickx B, Joly P, Thomas L; French Familial Melanoma Study Group, Bressac-de Paillerets B, Avril MF, Demenais F.

J Am Acad Dermatol. 2012 Dec;67(6):1257-64. doi: 10.1016/j.jaad.2012.05.014. Epub 2012 Jul 26.

​

Decreased efficiency of MSH6 mRNA polyadenylation linked to a 20-base-pair duplication in Lynch syndrome families.

Decorsière A, Toulas C, Fouque F, Tilkin-Mariamé AF, Selves J, Guimbaud R, Chipoulet E, Delmas C, Rey JM, Pujol P, Favre G, Millevoi S, Vagner S.

Cell Cycle. 2012 Jul 1;11(13):2578-80. doi: 10.4161/cc.20625. Epub 2012 Jul 1. No abstract available.

​

Association of PHB 1630 C>T and MTHFR 677 C>T polymorphisms with breast and ovarian cancer risk in BRCA1/2 mutation carriers: results from a multicenter study.

Jakubowska A, Rozkrut D, Antoniou A, Hamann U, Scott RJ, McGuffog L, Healy S, Sinilnikova OM, Rennert G, Lejbkowicz F, Flugelman A, Andrulis IL, Glendon G, Ozcelik H; OCGN, Thomassen M, Paligo M, Aretini P; SWE-BRCA, Kantala J, Aroer B, von Wachenfeldt A, Liljegren A, Loman N, Herbst K, Kristoffersson U, Rosenquist R, Karlsson P, Stenmark-Askmalm M, Melin B, Nathanson KL, Domchek SM, Byrski T, Huzarski T, Gronwald J, Menkiszak J, Cybulski C, Serrano P, Osorio A, Cajal TR, Tsitlaidou M, Benítez J, Gilbert M; HEBON, Rookus M, Aalfs CM, Kluijt I, Boessenkool-Pape JL, Meijers-Heijboer HE, Oosterwijk JC, van Asperen CJ, Blok MJ, Nelen MR, van den Ouweland AM, Seynaeve C, van der Luijt RB, Devilee P; EMBRACE, Easton DF, Peock S, Frost D, Platte R, Ellis SD, Fineberg E, Evans DG, Lalloo F, Eeles R, Jacobs C, Adlard J, Davidson R, Eccles D, Cole T, Cook J, Godwin A, Bove B; GEMO Study Collaborators, Stoppa-Lyonnet D, Caux-Moncoutier V, Belotti M, Tirapo C, Mazoyer S, Barjhoux L, Boutry-Kryza N, Pujol P, Coupier I, Peyrat JP, Vennin P, Muller D, Fricker JP, Venat-Bouvet L, Johannsson OT, Isaacs C, Schmutzler R, Wappenschmidt B, Meindl A, Arnold N, Varon-Mateeva R, Niederacher D, Sutter C, Deissler H, Preisler-Adams S, Simard J, Soucy P, Durocher F, Chenevix-Trench G, Beesley J, Chen X; KConFab, Rebbeck T, Couch F, Wang X, Lindor N, Fredericksen Z, Pankratz VS, Peterlongo P, Bonanni B, Fortuzzi S, Peissel B, Szabo C, Mai PL, Loud JT, Lubinski J; CIMBA, the Consortium of Investigators of Modifiers of BRCA1/2-Related Cancer.

Br J Cancer. 2012 Jun 5;106(12):2016-24. doi: 10.1038/bjc.2012.160. Epub 2012 May 15.

​

Long-term treatment with the pure anti-estrogen fulvestrant durably remodels estrogen signaling in BG-1 ovarian cancer cells.

Badia E, Docquier A, Busson M, Lapierre M, Pujol P, Balaguer P, Cavailles V.

J Steroid Biochem Mol Biol. 2012 Oct;132(1-2):176-85. doi: 10.1016/j.jsbmb.2012.05.006. Epub 2012 May 29.

​

Effects of BRCA2 cis-regulation in normal breast and cancer risk amongst BRCA2 mutation carriers.

Maia AT, Antoniou AC, O'Reilly M, Samarajiwa S, Dunning M, Kartsonaki C, Chin SF, Curtis CN, McGuffog L, Domchek SM; EMBRACE, Easton DF, Peock S, Frost D, Evans DG, Eeles R, Izatt L, Adlard J, Eccles D; GEMO Study Collaborators, Sinilnikova OM, Mazoyer S, Stoppa-Lyonnet D, Gauthier-Villars M, Faivre L, Venat-Bouvet L, Delnatte C, Nevanlinna H, Couch FJ, Godwin AK, Caligo MA; SWE-BRCA, Barkardottir RB; kConFab Investigators, Chen X, Beesley J, Healey S, Caldas C, Chenevix-Trench G, Ponder BA.

Breast Cancer Res. 2012 Apr 18;14(2):R63.

​

Common variants at the 19p13.1 and ZNF365 loci are associated with ER subtypes of breast cancer and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers.

Couch FJ, Gaudet MM, Antoniou AC, Ramus SJ, Kuchenbaecker KB, Soucy P, Beesley J, Chen X, Wang X, Kirchhoff T, McGuffog L, Barrowdale D, Lee A, Healey S, Sinilnikova OM, Andrulis IL; OCGN, Ozcelik H, Mulligan AM, Thomassen M, Gerdes AM, Jensen UB, Skytte AB, Kruse TA, Caligo MA, von Wachenfeldt A, Barbany-Bustinza G, Loman N, Soller M, Ehrencrona H, Karlsson P; SWE-BRCA, Nathanson KL, Rebbeck TR, Domchek SM, Jakubowska A, Lubinski J, Jaworska K, Durda K, Zlowocka E, Huzarski T, Byrski T, Gronwald J, Cybulski C, Górski B, Osorio A, Durán M, Tejada MI, Benitez J, Hamann U, Hogervorst FB; HEBON, van Os TA, van Leeuwen FE, Meijers-Heijboer HE, Wijnen J, Blok MJ, Kets M, Hooning MJ, Oldenburg RA, Ausems MG, Peock S, Frost D, Ellis SD, Platte R, Fineberg E, Evans DG, Jacobs C, Eeles RA, Adlard J, Davidson R, Eccles DM, Cole T, Cook J, Paterson J, Brewer C, Douglas F, Hodgson SV, Morrison PJ, Walker L, Porteous ME, Kennedy MJ, Side LE; EMBRACE, Bove B, Godwin AK, Stoppa-Lyonnet D; GEMO Study Collaborators, Fassy-Colcombet M, Castera L, Cornelis F, Mazoyer S, Léoné M, Boutry-Kryza N, Bressac-de Paillerets B, Caron O, Pujol P, Coupier I, Delnatte C, Akloul L, Lynch HT, Snyder CL, Buys SS, Daly MB, Terry M, Chung WK, John EM, Miron A, Southey MC, Hopper JL, Goldgar DE, Singer CF, Rappaport C, Tea MK, Fink-Retter A, Hansen TV, Nielsen FC, Arason A, Vijai J, Shah S, Sarrel K, Robson ME, Piedmonte M, Phillips K, Basil J, Rubinstein WS, Boggess J, Wakeley K, Ewart-Toland A, Montagna M, Agata S, Imyanitov EN, Isaacs C, Janavicius R, Lazaro C, Blanco I, Feliubadalo L, Brunet J, Gayther SA, Pharoah PP, Odunsi KO, Karlan BY, Walsh CS, Olah E, Teo SH, Ganz PA, Beattie MS, van Rensburg EJ, Dorfling CM, Diez O, Kwong A, Schmutzler RK, Wappenschmidt B, Engel C, Meindl A, Ditsch N, Arnold N, Heidemann S, Niederacher D, Preisler-Adams S, Gadzicki D, Varon-Mateeva R, Deissler H, Gehrig A, Sutter C, Kast K, Fiebig B, Heinritz W, Caldes T, de la Hoya M, Muranen TA, Nevanlinna H, Tischkowitz MD, Spurdle AB, Neuhausen SL, Ding YC, Lindor NM, Fredericksen Z, Pankratz VS, Peterlongo P, Manoukian S, Peissel B, Zaffaroni D, Barile M, Bernard L, Viel A, Giannini G, Varesco L, Radice P, Greene MH, Mai PL, Easton DF, Chenevix-Trench G; kConFab investigators, Offit K, Simard J; Consortium of Investigators of Modifiers of BRCA1/2.

Cancer Epidemiol Biomarkers Prev. 2012 Apr;21(4):645-57. doi: 10.1158/1055-9965.EPI-11-0888. Epub 2012 Feb 20.

​

Ovarian cancer susceptibility alleles and risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers.

Ramus SJ, Antoniou AC, Kuchenbaecker KB, Soucy P, Beesley J, Chen X, McGuffog L, Sinilnikova OM, Healey S, Barrowdale D, Lee A, Thomassen M, Gerdes AM, Kruse TA, Jensen UB, Skytte AB, Caligo MA, Liljegren A, Lindblom A, Olsson H, Kristoffersson U, Stenmark-Askmalm M, Melin B; SWE-BRCA, Domchek SM, Nathanson KL, Rebbeck TR, Jakubowska A, Lubinski J, Jaworska K, Durda K, Złowocka E, Gronwald J, Huzarski T, Byrski T, Cybulski C, Toloczko-Grabarek A, Osorio A, Benitez J, Duran M, Tejada MI, Hamann U, Rookus M, van Leeuwen FE, Aalfs CM, Meijers-Heijboer HE, van Asperen CJ, van Roozendaal KE, Hoogerbrugge N, Collée JM, Kriege M, van der Luijt RB; HEBON; EMBRACE, Peock S, Frost D, Ellis SD, Platte R, Fineberg E, Evans DG, Lalloo F, Jacobs C, Eeles R, Adlard J, Davidson R, Eccles D, Cole T, Cook J, Paterson J, Douglas F, Brewer C, Hodgson S, Morrison PJ, Walker L, Porteous ME, Kennedy MJ, Pathak H, Godwin AK, Stoppa-Lyonnet D, Caux-Moncoutier V, de Pauw A, Gauthier-Villars M, Mazoyer S, Léoné M, Calender A, Lasset C, Bonadona V, Hardouin A, Berthet P, Bignon YJ, Uhrhammer N, Faivre L, Loustalot C; GEMO, Buys S, Daly M, Miron A, Terry MB, Chung WK, John EM, Southey M, Goldgar D, Singer CF, Tea MK, Pfeiler G, Fink-Retter A, Hansen Tv, Ejlertsen B, Johannsson OT, Offit K, Kirchhoff T, Gaudet MM, Vijai J, Robson M, Piedmonte M, Phillips KA, Van Le L, Hoffman JS, Ewart Toland A, Montagna M, Tognazzo S, Imyanitov E, Issacs C, Janavicius R, Lazaro C, Blanco I, Tornero E, Navarro M, Moysich KB, Karlan BY, Gross J, Olah E, Vaszko T, Teo SH, Ganz PA, Beattie MS, Dorfling CM, van Rensburg EJ, Diez O, Kwong A, Schmutzler RK, Wappenschmidt B, Engel C, Meindl A, Ditsch N, Arnold N, Heidemann S, Niederacher D, Preisler-Adams S, Gadzicki D, Varon-Mateeva R, Deissler H, Gehrig A, Sutter C, Kast K, Fiebig B, Schäfer D, Caldes T, de la Hoya M, Nevanlinna H, Aittomäki K, Plante M, Spurdle AB; kConFab, Neuhausen SL, Ding YC, Wang X, Lindor N, Fredericksen Z, Pankratz VS, Peterlongo P, Manoukian S, Peissel B, Zaffaroni D, Bonanni B, Bernard L, Dolcetti R, Papi L, Ottini L, Radice P, Greene MH, Mai PL, Andrulis IL, Glendon G, Ozcelik H; OCGN, Pharoah PD, Gayther SA, Simard J, Easton DF, Couch FJ, Chenevix-Trench G; Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA).

Hum Mutat. 2012 Apr;33(4):690-702. doi: 10.1002/humu.22025. Epub 2012 Feb 14.

​

Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA).

Mavaddat N, Barrowdale D, Andrulis IL, Domchek SM, Eccles D, Nevanlinna H, Ramus SJ, Spurdle A, Robson M, Sherman M, Mulligan AM, Couch FJ, Engel C, McGuffog L, Healey S, Sinilnikova OM, Southey MC, Terry MB, Goldgar D, O'Malley F, John EM, Janavicius R, Tihomirova L, Hansen TV, Nielsen FC, Osorio A, Stavropoulou A, Benítez J, Manoukian S, Peissel B, Barile M, Volorio S, Pasini B, Dolcetti R, Putignano AL, Ottini L, Radice P, Hamann U, Rashid MU, Hogervorst FB, Kriege M, van der Luijt RB; HEBON, Peock S, Frost D, Evans DG, Brewer C, Walker L, Rogers MT, Side LE, Houghton C; EMBRACE, Weaver J, Godwin AK, Schmutzler RK, Wappenschmidt B, Meindl A, Kast K, Arnold N, Niederacher D, Sutter C, Deissler H, Gadzicki D, Preisler-Adams S, Varon-Mateeva R, Schönbuchner I, Gevensleben H, Stoppa-Lyonnet D, Belotti M, Barjhoux L; GEMO Study Collaborators, Isaacs C, Peshkin BN, Caldes T, de la Hoya M, Cañadas C, Heikkinen T, Heikkilä P, Aittomäki K, Blanco I, Lazaro C, Brunet J, Agnarsson BA, Arason A, Barkardottir RB, Dumont M, Simard J, Montagna M, Agata S, D'Andrea E, Yan M, Fox S; kConFab Investigators, Rebbeck TR, Rubinstein W, Tung N, Garber JE, Wang X, Fredericksen Z, Pankratz VS, Lindor NM, Szabo C, Offit K, Sakr R, Gaudet MM, Singer CF, Tea MK, Rappaport C, Mai PL, Greene MH, Sokolenko A, Imyanitov E, Toland AE, Senter L, Sweet K, Thomassen M, Gerdes AM, Kruse T, Caligo M, Aretini P, Rantala J, von Wachenfeld A, Henriksson K; SWE-BRCA Collaborators, Steele L, Neuhausen SL, Nussbaum R, Beattie M, Odunsi K, Sucheston L, Gayther SA, Nathanson K, Gross J, Walsh C, Karlan B, Chenevix-Trench G, Easton DF, Antoniou AC; Consortium of Investigators of Modifiers of BRCA1/2.

Cancer Epidemiol Biomarkers Prev. 2012 Jan;21(1):134-47. doi: 10.1158/1055-9965.EPI-11-0775. Epub 2011 Dec 5.

​

Common breast cancer susceptibility alleles are associated with tumour subtypes in BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2.

Mulligan AM, Couch FJ, Barrowdale D, Domchek SM, Eccles D, Nevanlinna H, Ramus SJ, Robson M, Sherman M, Spurdle AB, Wappenschmidt B, Lee A, McGuffog L, Healey S, Sinilnikova OM, Janavicius R, Hansen Tv, Nielsen FC, Ejlertsen B, Osorio A, Muñoz-Repeto I, Durán M, Godino J, Pertesi M, Benítez J, Peterlongo P, Manoukian S, Peissel B, Zaffaroni D, Cattaneo E, Bonanni B, Viel A, Pasini B, Papi L, Ottini L, Savarese A, Bernard L, Radice P, Hamann U, Verheus M, Meijers-Heijboer HE, Wijnen J, Gómez García EB, Nelen MR, Kets CM, Seynaeve C, Tilanus-Linthorst MM, van der Luijt RB, van Os T, Rookus M, Frost D, Jones JL, Evans DG, Lalloo F, Eeles R, Izatt L, Adlard J, Davidson R, Cook J, Donaldson A, Dorkins H, Gregory H, Eason J, Houghton C, Barwell J, Side LE, McCann E, Murray A, Peock S, Godwin AK, Schmutzler RK, Rhiem K, Engel C, Meindl A, Ruehl I, Arnold N, Niederacher D, Sutter C, Deissler H, Gadzicki D, Kast K, Preisler-Adams S, Varon-Mateeva R, Schoenbuchner I, Fiebig B, Heinritz W, Schäfer D, Gevensleben H, Caux-Moncoutier V, Fassy-Colcombet M, Cornelis F, Mazoyer S, Léoné M, Boutry-Kryza N, Hardouin A, Berthet P, Muller D, Fricker JP, Mortemousque I, Pujol P, Coupier I, Lebrun M, Kientz C, Longy M, Sevenet N, Stoppa-Lyonnet D, Isaacs C, Caldes T, de la Hoya M, Heikkinen T, Aittomäki K, Blanco I, Lazaro C, Barkardottir RB, Soucy P, Dumont M, Simard J, Montagna M, Tognazzo S, D'Andrea E, Fox S, Yan M, Rebbeck T, Olopade O, Weitzel JN, Lynch HT, Ganz PA, Tomlinson GE, Wang X, Fredericksen Z, Pankratz VS, Lindor NM, Szabo C, Offit K, Sakr R, Gaudet M, Bhatia J, Kauff N, Singer CF, Tea MK, Gschwantler-Kaulich D, Fink-Retter A, Mai PL, Greene MH, Imyanitov E, O'Malley FP, Ozcelik H, Glendon G, Toland AE, Gerdes AM, Thomassen M, Kruse TA, Jensen UB, Skytte AB, Caligo MA, Soller M, Henriksson K, Wachenfeldt vA, Arver B, Stenmark-Askmalm M, Karlsson P, Ding YC, Neuhausen SL, Beattie M, Pharoah PD, Moysich KB, Nathanson KL, Karlan BY, Gross J, John EM, Daly MB, Buys SM, Southey MC, Hopper JL, Terry MB, Chung W, Miron AF, Goldgar D, Chenevix-Trench G, Easton DF, Andrulis IL, Antoniou AC; Breast Cancer Family Registry; EMBRACE; GEMO Study Collaborators; HEBON; kConFab Investigators; Ontario Cancer Genetics Network; SWE-BRCA; CIMBA.

Breast Cancer Res. 2011;13(6):R110. doi: 10.1186/bcr3052. Epub 2011 Nov 2.

​

Common variants of the BRCA1 wild-type allele modify the risk of breast cancer in BRCA1 mutation carriers.

Cox DG, Simard J, Sinnett D, Hamdi Y, Soucy P, Ouimet M, Barjhoux L, Verny-Pierre C, McGuffog L, Healey S, Szabo C, Greene MH, Mai PL, Andrulis IL; Ontario Cancer Genetics Network, Thomassen M, Gerdes AM, Caligo MA, Friedman E, Laitman Y, Kaufman B, Paluch SS, Borg Å, Karlsson P, Askmalm MS, Bustinza GB; SWE-BRCA Collaborators, Nathanson KL, Domchek SM, Rebbeck TR, Benítez J, Hamann U, Rookus MA, van den Ouweland AM, Ausems MG, Aalfs CM, van Asperen CJ, Devilee P, Gille HJ; HEBON; EMBRACE, Peock S, Frost D, Evans DG, Eeles R, Izatt L, Adlard J, Paterson J, Eason J, Godwin AK, Remon MA, Moncoutier V, Gauthier-Villars M, Lasset C, Giraud S, Hardouin A, Berthet P, Sobol H, Eisinger F, Bressac de Paillerets B, Caron O, Delnatte C; GEMO Study Collaborators, Goldgar D, Miron A, Ozcelik H, Buys S, Southey MC, Terry MB; Breast Cancer Family Registry, Singer CF, Dressler AC, Tea MK, Hansen TV, Johannsson O, Piedmonte M, Rodriguez GC, Basil JB, Blank S, Toland AE, Montagna M, Isaacs C, Blanco I, Gayther SA, Moysich KB, Schmutzler RK, Wappenschmidt B, Engel C, Meindl A, Ditsch N, Arnold N, Niederacher D, Sutter C, Gadzicki D, Fiebig B, Caldes T, Laframboise R, Nevanlinna H, Chen X, Beesley J, Spurdle AB, Neuhausen SL, Ding YC, Couch FJ, Wang X, Peterlongo P, Manoukian S, Bernard L, Radice P, Easton DF, Chenevix-Trench G, Antoniou AC, Stoppa-Lyonnet D, Mazoyer S, Sinilnikova OM; Consortium of Investigators of Modifiers of BRCA1/2.

Hum Mol Genet. 2011 Dec 1;20(23):4732-47. doi: 10.1093/hmg/ddr388. Epub 2011 Sep 2.

​

Exemestane for breast-cancer prevention in postmenopausal women.

Goss PE, Ingle JN, Alés-Martínez JE, Cheung AM, Chlebowski RT, Wactawski-Wende J, McTiernan A, Robbins J, Johnson KC, Martin LW, Winquist E, Sarto GE, Garber JE, Fabian CJ, Pujol P, Maunsell E, Farmer P, Gelmon KA, Tu D, Richardson H; NCIC CTG MAP.3 Study Investigators.

N Engl J Med. 2011 Jun 23;364(25):2381-91. doi: 10.1056/NEJMoa1103507. Epub 2011 Jun 4. Erratum in: N Engl J Med. 2011 Oct 6;365(14):1361.

​

Common alleles at 6q25.1 and 1p11.2 are associated with breast cancer risk for BRCA1 and BRCA2 mutation carriers.

Antoniou AC, Kartsonaki C, Sinilnikova OM, Soucy P, McGuffog L, Healey S, Lee A, Peterlongo P, Manoukian S, Peissel B, Zaffaroni D, Cattaneo E, Barile M, Pensotti V, Pasini B, Dolcetti R, Giannini G, Putignano AL, Varesco L, Radice P, Mai PL, Greene MH, Andrulis IL, Glendon G, Ozcelik H, Thomassen M, Gerdes AM, Kruse TA, Birk Jensen U, Crüger DG, Caligo MA, Laitman Y, Milgrom R, Kaufman B, Paluch-Shimon S, Friedman E, Loman N, Harbst K, Lindblom A, Arver B, Ehrencrona H, Melin B; SWE-BRCA, Nathanson KL, Domchek SM, Rebbeck T, Jakubowska A, Lubinski J, Gronwald J, Huzarski T, Byrski T, Cybulski C, Gorski B, Osorio A, Ramón y Cajal T, Fostira F, Andrés R, Benitez J, Hamann U, Hogervorst FB, Rookus MA, Hooning MJ, Nelen MR, van der Luijt RB, van Os TA, van Asperen CJ, Devilee P, Meijers-Heijboer HE, Gómez Garcia EB; HEBON, Peock S, Cook M, Frost D, Platte R, Leyland J, Evans DG, Lalloo F, Eeles R, Izatt L, Adlard J, Davidson R, Eccles D, Ong KR, Cook J, Douglas F, Paterson J, Kennedy MJ, Miedzybrodzka Z; EMBRACE, Godwin A, Stoppa-Lyonnet D, Buecher B, Belotti M, Tirapo C, Mazoyer S, Barjhoux L, Lasset C, Leroux D, Faivre L, Bronner M, Prieur F, Nogues C, Rouleau E, Pujol P, Coupier I, Frénay M; CEMO Study Collaborators, Hopper JL, Daly MB, Terry MB, John EM, Buys SS, Yassin Y, Miron A, Goldgar D; Breast Cancer Family Registry, Singer CF, Tea MK, Pfeiler G, Dressler AC, Hansen Tv, Jønson L, Ejlertsen B, Barkardottir RB, Kirchhoff T, Offit K, Piedmonte M, Rodriguez G, Small L, Boggess J, Blank S, Basil J, Azodi M, Toland AE, Montagna M, Tognazzo S, Agata S, Imyanitov E, Janavicius R, Lazaro C, Blanco I, Pharoah PD, Sucheston L, Karlan BY, Walsh CS, Olah E, Bozsik A, Teo SH, Seldon JL, Beattie MS, van Rensburg EJ, Sluiter MD, Diez O, Schmutzler RK, Wappenschmidt B, Engel C, Meindl A, Ruehl I, Varon-Mateeva R, Kast K, Deissler H, Niederacher D, Arnold N, Gadzicki D, Schönbuchner I, Caldes T, de la Hoya M, Nevanlinna H, Aittomäki K, Dumont M, Chiquette J, Tischkowitz M, Chen X, Beesley J, Spurdle AB; kConFab investigators, Neuhausen SL, Chun Ding Y, Fredericksen Z, Wang X, Pankratz VS, Couch F, Simard J, Easton DF, Chenevix-Trench G; CIMBA.

Hum Mol Genet. 2011 Aug 15;20(16):3304-21. doi: 10.1093/hmg/ddr226. Epub 2011 May 18.

​

The rs2910164:G>C SNP in the MIR146A gene is not associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers.

Garcia AI, Cox DG, Barjhoux L, Verny-Pierre C, Barnes D; Gemo Study Collaborators, Antoniou AC, Stoppa-Lyonnet D, Sinilnikova OM, Mazoyer S.

Hum Mutat. 2011 Sep;32(9):1004-7. doi: 10.1002/humu.21539. Epub 2011 Jul 12.

​

Common genetic variation at BARD1 is not associated with breast cancer risk in BRCA1 or BRCA2 mutation carriers.

Spurdle AB, Marquart L, McGuffog L, Healey S, Sinilnikova O, Wan F, Chen X, Beesley J, Singer CF, Dressler AC, Gschwantler-Kaulich D, Blum JL, Tung N, Weitzel J, Lynch H, Garber J, Easton DF, Peock S, Cook M, Oliver CT, Frost D, Conroy D, Evans DG, Lalloo F, Eeles R, Izatt L, Davidson R, Chu C, Eccles D, Selkirk CG, Daly M, Isaacs C, Stoppa-Lyonnet D, Sinilnikova OM, Buecher B, Belotti M, Mazoyer S, Barjhoux L, Verny-Pierre C, Lasset C, Dreyfus H, Pujol P, Collonge-Rame MA; GEMO Study Collaborators, Rookus MA, Verhoef S, Kriege M, Hoogerbrugge N, Ausems MG, van Os TA, Wijnen J, Devilee P, Meijers-Heijboer HE, Blok MJ, Heikkinen T, Nevanlinna H, Jakubowska A, Lubinski J, Huzarski T, Byrski T, Durocher F, Couch FJ, Lindor NM, Wang X, Thomassen M, Domchek S, Nathanson K, Caligo M, Jernström H, Liljegren A, Ehrencrona H, Karlsson P; SWE-BRCA, Ganz PA, Olopade OI, Tomlinson G, Neuhausen S, Antoniou AC, Chenevix-Trench G, Rebbeck TR.

Cancer Epidemiol Biomarkers Prev. 2011 May;20(5):1032-8. doi: 10.1158/1055-9965.EPI-10-0909. Epub 2011 Mar 10.

​

[Cancer genetics: estimation of the needs of the population in France for the next ten years].

Bonaïti-Pellié C, Andrieu N, Arveux P, Bonadona V, Buecher B, Delpech M, Jolly D, Julian-Reynier C, Luporsi E, Noguès C, Nowak F, Olschwang S, Orsi F, Pujol P, Saurin JC, Sinilnikova O, Stoppa-Lyonnet D, Thépot F.

Bull Cancer. 2009 Sep;96(9):875-900. doi: 10.1684/bdc.2009.0943. Review. French.

​

Constitutional 11p15 abnormalities, including heritable imprinting center mutations, cause nonsyndromic Wilms tumor.

Scott RH, Douglas J, Baskcomb L, Huxter N, Barker K, Hanks S, Craft A, Gerrard M, Kohler JA, Levitt GA, Picton S, Pizer B, Ronghe MD, Williams D; Factors Associated with Childhood Tumours (FACT) Collaboration, Cook JA, Pujol P, Maher ER, Birch JM, Stiller CA, Pritchard-Jones K, Rahman N.

Nat Genet. 2008 Nov;40(11):1329-34. doi: 10.1038/ng.243. Epub 2008 Oct 5.

​

The contribution of large genomic deletions at the CDKN2A locus to the burden of familial melanoma.

Lesueur F, de Lichy M, Barrois M, Durand G, Bombled J, Avril MF, Chompret A, Boitier F, Lenoir GM; French Familial Melanoma Study Group, Bressac-de Paillerets B, Baccard M, Bachollet B, Berthet P, Bonadona V, Bonnetblanc JM, Caron O, Chevrant-Breton J, Cuny JF, Dalle S, Delaunay M, Demange L, De Quatrebarbes J, Doré JF, Frénay M, Fricker JP, Gauthier-Villars M, Gesta P, Giraud S, Gorry P, Grange F, Green A, Huiart L, Janin N, Joly P, Kérob D, Lasset C, Leroux D, Limacher JM, Longy M, Mansard S, Marrou K, Martin-Denavit T, Mateus C, Maubec E, Olivier-Faivre L, Orlandini V, Pujol P, Sassolas B, Stoppa-Lyonnet D, Thomas L, Vabres P, Venat L, Wierzbicka E, Zattara H.

Br J Cancer. 2008 Jul 22;99(2):364-70. doi: 10.1038/sj.bjc.6604470. Epub 2008 Jul 8.

​

An unusual succinate dehydrogenase gene mutation C in a case of laryngeal paraganglioma.

Garrel R, Raynaud P, Raingeard I, Muyshondt C, Gardiner Q, Guerrier B, Pujol P, Coupier I.

J Laryngol Otol. 2009 Jan;123(1):141-4. doi: 10.1017/S0022215107001570. Epub 2008 Feb 11.

​

Hormonal imbalance in two types of endometrial cancer and genetic polymorphism of steroidogenic enzymes.

Berstein L, Zimarina T, Imyanitov E, Kovalevskij A, Maximov S, Pujol P, Thijssen J.

Maturitas. 2006 Jul 20;54(4):352-5. Epub 2006 May 30.

​

Chordin is underexpressed in ovarian tumors and reduces tumor cell motility.

Moll F, Millet C, Noël D, Orsetti B, Bardin A, Katsaros D, Jorgensen C, Garcia M, Theillet C, Pujol P, François V.

FASEB J. 2006 Feb;20(2):240-50.

​

[Hereditary predispositions to gynaecological cancers].

Coupier I, Pujol P.

Gynecol Obstet Fertil. 2005 Nov;33(11):851-6. Epub 2005 Oct 26. French.

​

[Multivisceral resections of extracolorectal lesions in familial adenomatous polyposis].

Godlewski G, Leborgne J, Lehur A, Deixonne B, Bourgaux JF, Dehni N, Pujol P, Prudhomme M.

Ann Chir. 2005 Dec;130(10):618-23. Epub 2005 Oct 6. French.

​

Is BRCA1/BRCA2-related breast carcinogenesis estrogen dependent?

Noruzinia M, Coupier I, Pujol P.

Cancer. 2005 Oct 15;104(8):1567-74. Review.

​

The nuclear receptor liver receptor homolog-1 is an estrogen receptor target gene.

Annicotte JS, Chavey C, Servant N, Teyssier J, Bardin A, Licznar A, Badia E, Pujol P, Vignon F, Maudelonde T, Lazennec G, Cavailles V, Fajas L.

Oncogene. 2005 Dec 8;24(55):8167-75.

​

Aromatase expression in ovarian epithelial cancers.

Cunat S, Rabenoelina F, Daurès JP, Katsaros D, Sasano H, Miller WR, Maudelonde T, Pujol P.

J Steroid Biochem Mol Biol. 2005 Jan;93(1):15-24.

​

Letrozole sensitizes breast cancer cells to ionizing radiation.

Azria D, Larbouret C, Cunat S, Ozsahin M, Gourgou S, Martineau P, Evans DB, Romieu G, Pujol P, Pèlegrin A.

Breast Cancer Res. 2005;7(1):R156-63. Epub 2004 Dec 7.

​

Six novel heterozygous MLH1, MSH2, and MSH6 and one homozygous MLH1 germline mutations in hereditary nonpolyposis colorectal cancer.

Rey JM, Noruzinia M, Brouillet JP, Sarda P, Maudelonde T, Pujol P.

Cancer Genet Cytogenet. 2004 Dec;155(2):149-51.

​

Transcriptional and posttranscriptional regulation of fibulin-1 by estrogens leads to differential induction of messenger ribonucleic acid variants in ovarian and breast cancer cells.

Bardin A, Moll F, Margueron R, Delfour C, Chu ML, Maudelonde T, Cavailles V, Pujol P.

Endocrinology. 2005 Feb;146(2):760-8. Epub 2004 Nov 4.

​

[Are the hereditary forms of BRCA1 and BRCA2 breast cancer sensitive to estrogens?].

Pujol P, This P, Noruzinia M, Stoppa-Lyonnet D, Maudelonde T.

Bull Cancer. 2004 Jul-Aug;91(7-8):583-91. Review. French.

​

Loss of ERbeta expression as a common step in estrogen-dependent tumor progression.

Bardin A, Boulle N, Lazennec G, Vignon F, Pujol P.

Endocr Relat Cancer. 2004 Sep;11(3):537-51. Review.

​

Involvement of estrogen receptor beta in ovarian carcinogenesis.

Bardin A, Hoffmann P, Boulle N, Katsaros D, Vignon F, Pujol P, Lazennec G.

Cancer Res. 2004 Aug 15;64(16):5861-9. Retraction in: Lazennec G. Cancer Res. 2005 Jun 15;65(12):5480.

​

Estrogens and epithelial ovarian cancer.

Cunat S, Hoffmann P, Pujol P.

Gynecol Oncol. 2004 Jul;94(1):25-32. Review.

​

Progesterone receptor quantification as a strong prognostic determinant in postmenopausal breast cancer women under tamoxifen therapy.

Lamy PJ, Pujol P, Thezenas S, Kramar A, Rouanet P, Guilleux F, Grenier J.

Breast Cancer Res Treat. 2002 Nov;76(1):65-71.

​

Significant contribution of large BRCA1 gene rearrangements in 120 French breast and ovarian cancer families.

Gad S, Caux-Moncoutier V, Pagès-Berhouet S, Gauthier-Villars M, Coupier I, Pujol P, Frénay M, Gilbert B, Maugard C, Bignon YJ, Chevrier A, Rossi A, Fricker JP, Nguyen TD, Demange L, Aurias A, Bensimon A, Stoppa-Lyonnet D.

Oncogene. 2002 Oct 3;21(44):6841-7.

​

[Genetic alterations of transcription cofactors in solid tumors].

Rouayrenc JF, Castet A, Rey JM, Brouillet JP, Pujol P, Vignon F, Maudelonde T, Cavaillès V.

Bull Cancer. 2002 Apr;89(4):357-64. Review. French.

​

Estrogen induction and overexpression of fibulin-1C mRNA in ovarian cancer cells.

Moll F, Katsaros D, Lazennec G, Hellio N, Roger P, Giacalone PL, Chalbos D, Maudelonde T, Rochefort H, Pujol P.

Oncogene. 2002 Feb 7;21(7):1097-107.

​

Novel germline RET mutation segregating with papillary thyroid carcinomas.

Rey JM, Brouillet JP, Fonteneau-Allaire J, Boneu A, Bastié D, Maudelonde T, Pujol P.

Genes Chromosomes Cancer. 2001 Dec;32(4):390-1.

​

Analysis of the potential contribution of estrogen receptor (ER) beta in ER cytosolic assay of breast cancer.

Brouillet JP, Dujardin MA, Chalbos D, Rey JM, Grenier J, Lamy PJ, Maudelonde T, Pujol P.

Int J Cancer. 2001 Jul 20;95(4):205-8.

​

A prospective prognostic study of the hormonal milieu at the time of surgery in premenopausal breast carcinoma.

Pujol P, Daures JP, Brouillet JP, Chang S, Rouanet P, Bringer J, Grenier J, Maudelonde T.

Cancer. 2001 May 15;91(10):1854-61.

​

[Non-genomic steroid effects: estrogen action revisited].

Rouayrenc JF, Vignon F, Bringer J, Pujol P.

Ann Endocrinol (Paris). 2000 Dec;61(6):517-523. Review. French.

​

Neoadjuvant tamoxifen for operable breast cancer: a need for phase III studies?

Pujol P, Daures JP, Rouanet P, Hermand J, Domergue J, Grenier J, Maudelonde T.

Cancer Detect Prev. 2000;24(5):445-51.

​

Semiquantitative reverse transcription-polymerase chain reaction to evaluate the expression patterns of genes involved in the oestrogen pathway.

Rey JM, Pujol P, Callier P, Cavailles V, Freiss G, Maudelonde T, Brouillet JP.

J Mol Endocrinol. 2000 Jun;24(3):433-40.

​

[Anti-estrogens, selective estrogen receptor modulators (SERM), tibolone: modes of action].

Maudelonde T, Brouillet JP, Pujol P.

Contracept Fertil Sex. 1999 Sep;27(9):620-4. Review. French.

​

Time at surgery during menstrual cycle and menopause affects pS2 but not cathepsin D levels in breast cancer.

Pujol P, Daurès JP, Brouillet JP, Maudelonde T, Rochefort H, Grenier J.

Br J Cancer. 1999 Feb;79(5-6):909-14.

​

Differential expression of estrogen receptor-alpha and -beta messenger RNAs as a potential marker of ovarian carcinogenesis.

Pujol P, Rey JM, Nirde P, Roger P, Gastaldi M, Laffargue F, Rochefort H, Maudelonde T.

Cancer Res. 1998 Dec 1;58(23):5367-73.

​

67.Increased immunostaining of fibulin-1, an estrogen-regulated protein in the stroma of human ovarian epithelial tumors.

Roger P, Pujol P, Lucas A, Baldet P, Rochefort H.

Am J Pathol. 1998 Nov;153(5):1579-88.

​

Changing estrogen and progesterone receptor patterns in breast carcinoma during the menstrual cycle and menopause.

Pujol P, Daures JP, Thezenas S, Guilleux F, Rouanet P, Grenier J.

Cancer. 1998 Aug 15;83(4):698-705.

P

Expression of oestrogen receptor-alpha splicing variants and oestrogen receptor-beta in endometrium of infertile patients.

Rey JM, Pujol P, Dechaud H, Edouard E, Hedon B, Maudelonde T.

Mol Hum Reprod. 1998 Jul;4(7):641-7.

​

TSH suppression combined with carbimazole for Graves' disease: effect on remission and relapse rates.

Pujol P, Osman A, Grabar S, Daurès JP, Galtier-Dereure F, Boegner C, Baldet L, Raye R, Bringer J, Jaffiol C.

Clin Endocrinol (Oxf). 1998 May;48(5):635-40.

​

Obesity and breast cancer risk.

Pujol P, Galtier-Dereure F, Bringer J.

Hum Reprod. 1997 Oct;12 Suppl 1:116-25. Review.

​

Choice of stimulation in polycystic ovarian syndrome: the influence of obesity.

Galtier-Dereure F, Pujol P, Dewailly D, Bringer J.

Hum Reprod. 1997 Oct;12 Suppl 1:88-96. Review.

​

[Long term follow up of medical treatment of differentiated thyroid cancer].

Jaffiol C, Daures JP, Nsakala N, Guerenova J, Baldet L, Pujol P, Vannereau D, Bringer J.

Ann Endocrinol (Paris). 1995;56(2):119-26. French.

​

Degree of thyrotropin suppression as a prognostic determinant in differentiated thyroid cancer.

Pujol P, Daures JP, Nsakala N, Baldet L, Bringer J, Jaffiol C.

J Clin Endocrinol Metab. 1996 Dec;81(12):4318-23.

​

Prevention of thyroid neoplasm recurrence with Triac and levothyroxine.

Pujol P, Osman A, Bringer J, Jaffiol C.

Clin Endocrinol (Oxf). 1997 Jan;46(1):121-2. No abstract available.

​

[Estrogen receptors and breast cancer].

Maudelonde T, Pujol P, Rochefort H.

Rev Prat. 1994 May 15;44(10):1299-303. French.

​

Rising levels of estrogen receptor in breast cancer over 2 decades.

Pujol P, Hilsenbeck SG, Chamness GC, Elledge RM.

Cancer. 1994 Sep 1;74(5):1601-6.

​

In vivo stimulation by tamoxifen of cathepsin D RNA level in breast cancer.

Maudelonde T, Escot C, Pujol P, Rouanet P, Defrenne A, Brouillet JP, Rochefort H.

Eur J Cancer. 1994;30A(14):2049-53.

​

Why are estrogen-receptor-negative breast cancers more aggressive than the estrogen-receptor-positive breast cancers?

Sheikh MS, Garcia M, Pujol P, Fontana JA, Rochefort H.

Invasion Metastasis. 1994-1995;14(1-6):329-36. Review.

​

William L. McGuire Memorial Symposium. The role and prognostic significance of p53 gene alterations in breast cancer.

Elledge RM, Fuqua SA, Clark GM, Pujol P, Allred DC.

Breast Cancer Res Treat. 1993;27(1-2):95-102.

​

A prospective study of the prognostic value of cathepsin D levels in breast cancer cytosol.

Pujol P, Maudelonde T, Daures JP, Rouanet P, Brouillet JP, Pujol H, Rochefort H.

Cancer. 1993 Mar 15;71(6):2006-12.

​

Prognostic significance of p53 gene alterations in node-negative breast cancer.

Elledge RM, Fuqua SA, Clark GM, Pujol P, Allred DC, McGuire WL.

Breast Cancer Res Treat. 1993;26(3):225-35.

​

p53 mutations in ovarian cancer: a late event?

Mazars R, Pujol P, Maudelonde T, Jeanteur P, Theillet C.

Oncogene. 1991 Sep;6(9):1685-90.

​

Overexpression of transfected cathepsin D in transformed cells increases their malignant phenotype and metastatic potency.

Garcia M, Derocq D, Pujol P, Rochefort H.

Oncogene. 1990 Dec;5(12):1809-14.

​

[Use of guidelines and heterogeneity of decision making for adjuvant chemotherapy in hormone-receptor positive, HER2-negative, early breast cancer: results of a French national survey].

Fekih M, Petit T, Zarca D, Guinebretière JM, André F, Pierga JY, Namer M, Gligorov J, Delaloge S.

Bull Cancer. 2014 Oct;101(10):918-24. doi: 10.1684/bdc.2014.2030. French.

​

Patients' experiences following breast cancer treatment: an exploratory survey of personal and work experiences of breast cancer patients from three European countries.

Braybrooke JP, Mimoun S, Zarca D, Elia D, Pinder B, Lloyd AJ, Breheny K, Lomazzi M, Borisch B.

Eur J Cancer Care (Engl). 2015 Sep;24(5):650-61. doi: 10.1111/ecc.12222. Epub 2014 Jul 23.

​

Breast cancers and gene expression signatures: here and now].

Zarca D.

Gynecol Obstet Fertil. 2012 Oct;40(10):557-60. doi: 10.1016/j.gyobfe.2012.07.024. Epub 2012 Sep 14. French. No abstract available.

​

Secondary cytoreductive surgery in ovarian cancer.

Michel G, Zarca D, Castaigne D, Prade M.

Eur J Surg Oncol. 1989 Jun;15(3):201-4.

​

Chemotherapy by the intravenous and intraperitoneal routes combined in ovarian cancer.

Zylberberg B, Ravina JH, Salat-Baroux J, Madelenat P, Zarca D, Dormont D.

Gynecol Oncol. 1990 Feb;36(2):271-6.

​

[Sarcoma of the uterus. A clinical study apropos of 50 surgically treated cases at the Gustave Roussy Institute. Review of the literature].

Michel G, Pfeiffer F, Duvillard P, Prade M, Castaigne D, Zarca D, Pejovic-Lenfant MH, Gerbaulet A, Lhomme C.

J Gynecol Obstet Biol Reprod (Paris). 1989;18(8):1024-30. Review. French.

​

ISPOG European Consensus Statement - chronic pelvic pain in women (short version).

Siedentopf F, Weijenborg P, Engman M, Maier B, Cagnacci A, Mimoun S, Wenger A, Kentenich H.

J Psychosom Obstet Gynaecol. 2015;36(4):161-70. doi: 10.3109/0167482X.2015.1103732.

​

[Sexual pain disorders in females and males].

Monforte M, Mimoun S, Droupy S.

Prog Urol. 2013 Jul;23(9):761-70. doi: 10.1016/j.purol.2013.01.018. Epub 2013 Apr 4. Review. French.

​

[The gynaecologist and women's sexuality: end of an omission].

Buisson O, Buvat J, Mimoun S.

Gynecol Obstet Fertil. 2012 May;40(5):309. doi: 10.1016/j.gyobfe.2012.03.006. Epub 2012 May 9. French. No abstract available.

​

[Hypoactive sexual desire disorder, HSDD].

Mimoun S.

Gynecol Obstet Fertil. 2011 Jan;39(1):28-31. doi: 10.1016/j.gyobfe.2010.10.016. Epub 2010 Dec 24. Review. French.

​

Female sexual dysfunctions: definitions and classification.

Mimoun S, Wylie K.

Maturitas. 2009 Jun 20;63(2):116-8. doi: 10.1016/j.maturitas.2009.04.003. Epub 2009 May 23. Review.

​

Therapeutic options for postmenopausal female sexual dysfunction.

Al-Azzawi F, Bitzer J, Brandenburg U, Castelo-Branco C, Graziottin A, Kenemans P, Lachowsky M, Mimoun S, Nappi RE, Palacios S, Schwenkhagen A, Studd J, Wylie K, Zahradnik HP.

Climacteric. 2010 Apr;13(2):103-20. doi: 10.3109/13697130903437615. Review.

​

Sexual response models in women.

Wylie K, Mimoun S.

Maturitas. 2009 Jun 20;63(2):112-5. doi: 10.1016/j.maturitas.2009.03.007. Epub 2009 Apr 15. Review.

​

Breast cancer risk in postmenopausal women using testosterone in combination with hormone replacement therapy.

Bitzer J, Kenemans P, Mueck AO; FSDeducation Group.

Maturitas. 2008 Mar 20;59(3):209-18. doi: 10.1016/j.maturitas.2008.01.005. Epub 2008 Mar 14. Review.

​

Premature ejaculation: results from a five-country European observational study.

Giuliano F, Patrick DL, Porst H, La Pera G, Kokoszka A, Merchant S, Rothman M, Gagnon DD, Polverejan E; 3004 Study Group.

Eur Urol. 2008 May;53(5):1048-57. Epub 2007 Oct 16.

​

[Prostate cancer and sexuality].

Mimoun S.

Soins. 2007 Mar;(713):48-9. French. No abstract available.

​

[Menopause, andropause and sexual function].

Mimoun S.

Gynecol Obstet Fertil. 2003 Feb;31(2):141-6. Review. French.

​

[The experience of menstruation and its disorders in 603 women using contraception in 1999].

Mimoun S, Le MG, Buhler M, Costa A, Hosansky F.

Gynecol Obstet Fertil. 2000 Dec;28(12):904-12. French.

PMID:

​

[Menopause and sexuality].

Mimoun S.

Contracept Fertil Sex. 1996 Jan;24(1):62-6. Review. French.

​

[Prostaglandin E1 in the treatment of erectile insufficiency. Comparison of efficacy and tolerance based on different etiologies].

Desvaux P, Mimoun S.

J Urol (Paris). 1994;100(1):17-22. French.

​

[Sexual disorders after radical prostatectomy and their treatment. Psychological aspects].

Mimoun S, Desvaux P.

J Urol (Paris). 1994;100(3):147-9. French.

​

[The multiple interactions between infertility and sexuality].

Mimoun S.

Contracept Fertil Sex. 1993 Mar;21(3):251-4. Review. French.

​

​

​

​

​

CCL2/CCL5 secreted by the stroma induce IL-6/PYK2 dependent chemoresistance in ovarian cancer.

Pasquier J, Gosset M, Geyl C, Hoarau-Véchot J, Chevrot A, Pocard M, Mirshahi M, Lis R, Rafii A, Touboul C.

Mol Cancer. 2018 Feb 19;17(1):47. doi: 10.1186/s12943-018-0787-z.

​

Halfway between 2D and Animal Models: Are 3D Cultures the Ideal Tool to Study Cancer-Microenvironment Interactions?

Hoarau-Véchot J, Rafii A, Touboul C, Pasquier J.

Int J Mol Sci. 2018 Jan 18;19(1). pii: E181. doi: 10.3390/ijms19010181. Review.

​

Circulating microparticles in acute diabetic Charcot foot exhibit a high content of inflammatory cytokines, and support monocyte-to-osteoclast cell induction.

Pasquier J, Thomas B, Hoarau-Véchot J, Odeh T, Robay A, Chidiac O, Dargham SR, Turjoman R, Halama A, Fakhro K, Menzies R, Jayyousi A, Zirie M, Al Suwaidi J, Rafii A, Malik RA, Talal T, Abi Khalil C.

Sci Rep. 2017 Nov 27;7(1):16450. doi: 10.1038/s41598-017-16365-7.

​

MicroRNA-200, associated with metastatic breast cancer, promotes traits of mammary luminal progenitor cells.

Sánchez-Cid L, Pons M, Lozano JJ, Rubio N, Guerra-Rebollo M, Soriano A, Paris-Coderch L, Segura MF, Fueyo R, Arguimbau J, Zodda E, Bermudo R, Alonso I, Caparrós X, Cascante M, Rafii A, Kang Y, Martínez-Balbás M, Weiss SJ, Blanco J, Muñoz M, Fernández PL, Thomson TM.

Oncotarget. 2017 Sep 7;8(48):83384-83406. doi: 10.18632/oncotarget.20698. eCollection 2017 Oct 13.

​

Coculturing with endothelial cells promotes in vitro maturation and electrical coupling of human embryonic stem cell-derived cardiomyocytes.

Pasquier J, Gupta R, Rioult D, Hoarau-Véchot J, Courjaret R, Machaca K, Al Suwaidi J, Stanley EG, Rafii S, Elliott DA, Abi Khalil C, Rafii A.

J Heart Lung Transplant. 2017 Jun;36(6):684-693. doi: 10.1016/j.healun.2017.01.001. Epub 2017 Jan 10.

​

Nesting of colon and ovarian cancer cells in the endothelial niche is associated with alterations in glycan and lipid metabolism.

Halama A, Guerrouahen BS, Pasquier J, Satheesh NJ, Suhre K, Rafii A.

Sci Rep. 2017 Jan 4;7:39999. doi: 10.1038/srep39999.

PMID:

​

Complementarity of SOMAscan to LC-MS/MS and RNA-seq for quantitative profiling of human embryonic and mesenchymal stem cells.

Billing AM, Ben Hamidane H, Bhagwat AM, Cotton RJ, Dib SS, Kumar P, Hayat S, Goswami N, Suhre K, Rafii A, Graumann J.

J Proteomics. 2017 Jan 6;150:86-97. doi: 10.1016/j.jprot.2016.08.023. Epub 2016 Sep 6.

​

European Society of Gynaecologic Oncology Quality Indicators for Advanced Ovarian Cancer Surgery.

Querleu D, Planchamp F, Chiva L, Fotopoulou C, Barton D, Cibula D, Aletti G, Carinelli S, Creutzberg C, Davidson B, Harter P, Lundvall L, Marth C, Morice P, Rafii A, Ray-Coquard I, Rockall A, Sessa C, van der Zee A, Vergote I, du Bois A.

Int J Gynecol Cancer. 2016 Sep;26(7):1354-63. doi: 10.1097/IGC.0000000000000767.

​

GAPTrap: A Simple Expression System for Pluripotent Stem Cells and Their Derivatives.

Kao T, Labonne T, Niclis JC, Chaurasia R, Lokmic Z, Qian E, Bruveris FF, Howden SE, Motazedian A, Schiesser JV, Costa M, Sourris K, Ng E, Anderson D, Giudice A, Farlie P, Cheung M, Lamande SR, Penington AJ, Parish CL, Thomson LH, Rafii A, Elliott DA, Elefanty AG, Stanley EG.

Stem Cell Reports. 2016 Sep 13;7(3):518-526. doi: 10.1016/j.stemcr.2016.07.015. Epub 2016 Sep 1.

​

Recto-vaginal septum cystadenocarcinoma: a case report and review of the literature.

Warembourg S, Cayrac M, Rathat G, Rafii A.

BMC Womens Health. 2016 May 3;16:21. doi: 10.1186/s12905-016-0300-z. Review.

PMID:

​

Altered expression pattern of circular RNAs in primary and metastatic sites of epithelial ovarian carcinoma.

Ahmed I, Karedath T, Andrews SS, Al-Azwani IK, Mohamoud YA, Querleu D, Rafii A, Malek JA.

Oncotarget. 2016 Jun 14;7(24):36366-36381. doi: 10.18632/oncotarget.8917.

​

Integrative Analyses of Colorectal Cancer Show Immunoscore Is a Stronger Predictor of Patient Survival Than Microsatellite Instability.

Mlecnik B, Bindea G, Angell HK, Maby P, Angelova M, Tougeron D, Church SE, Lafontaine L, Fischer M, Fredriksen T, Sasso M, Bilocq AM, Kirilovsky A, Obenauf AC, Hamieh M, Berger A, Bruneval P, Tuech JJ, Sabourin JC, Le Pessot F, Mauillon J, Rafii A, Laurent-Puig P, Speicher MR, Trajanoski Z, Michel P, Sesboüe R, Frebourg T, Pagès F, Valge-Archer V, Latouche JB, Galon J.

​

Clinical practice guidelines from the French College of Gynecologists and Obstetricians (CNGOF): benign breast tumors - short text.

Lavoué V, Fritel X, Antoine M, Beltjens F, Bendifallah S, Boisserie-Lacroix M, Boulanger L, Canlorbe G, Catteau-Jonard S, Chabbert-Buffet N, Chamming's F, Chéreau E, Chopier J, Coutant C, Demetz J, Guilhen N, Fauvet R, Kerdraon O, Laas E, Legendre G, Mathelin C, Nadeau C, Naggara IT, Ngô C, Ouldamer L, Rafii A, Roedlich MN, Seror J, Séror JY, Touboul C, Uzan C, Daraï E; French College of Gynecologists and Obstetricians (CNGOF).

Eur J Obstet Gynecol Reprod Biol. 2016 May;200:16-23. doi: 10.1016/j.ejogrb.2016.02.017. Epub 2016 Feb 28.

PMID:

​

Correction: Preferential Allele Expression Analysis Identifies Shared Germline and Somatic Driver Genes in Advanced Ovarian Cancer.

Halabi NM, Martinez A, Al-Farsi H, Mery E, Puydenus L, Pujol P, Khalak HG, McLurcan C, Ferron G, Querleu D, Al-Azwani I, Al-Dous E, Mohamoud YA, Malek JA, Rafii A.

PLoS Genet. 2016 Feb 18;12(2):e1005892. doi: 10.1371/journal.pgen.1005892. eCollection 2016 Feb. No abstract available.

​

Comprehensive transcriptomic and proteomic characterization of human mesenchymal stem cells reveals source specific cellular markers.

Billing AM, Ben Hamidane H, Dib SS, Cotton RJ, Bhagwat AM, Kumar P, Hayat S, Yousri NA, Goswami N, Suhre K, Rafii A, Graumann J.

Sci Rep. 2016 Feb 9;6:21507. doi: 10.1038/srep21507.

​

Are Early Relapses in Advanced-Stage Ovarian Cancer Doomed to a Poor Prognosis?

Vidal F, Guerby P, Luyckx M, Haddad P, Stoeckle E, Morice P, Leblanc E, Lecuru F, Daraï E, Classe JM, Pomel C, Filleron T, Ferron G, Querleu D, Rafii A.

PLoS One. 2016 Jan 28;11(1):e0147787. doi: 10.1371/journal.pone.0147787. eCollection 2016.

​

Preferential Allele Expression Analysis Identifies Shared Germline and Somatic Driver Genes in Advanced Ovarian Cancer.

Halabi NM, Martinez A, Al-Farsi H, Mery E, Puydenus L, Pujol P, Khalak HG, McLurcan C, Ferron G, Querleu D, Al-Azwani I, Al-Dous E, Mohamoud YA, Malek JA, Rafii A.

PLoS Genet. 2016 Jan 6;12(1):e1005755. doi: 10.1371/journal.pgen.1005755. eCollection 2016 Jan. Erratum in: PLoS Genet. 2016 Feb;12(2):e1005892.

​

VE-cadherin cleavage by ovarian cancer microparticles induces β-catenin phosphorylation in endothelial cells.

Al Thawadi H, Abu-Kaoud N, Al Farsi H, Hoarau-Véchot J, Rafii S, Rafii A, Pasquier J.

Oncotarget. 2016 Feb 2;7(5):5289-305. doi: 10.18632/oncotarget.6677.

​

Which Surgical Attitude to Choose in the Context of Non-Resectability of Ovarian Carcinomatosis: Beyond Gross Residual Disease Considerations.

Vidal F, Al Thani H, Haddad P, Luyckx M, Stoeckle E, Morice P, Leblanc E, Lecuru F, Daraï E, Classe JM, Pomel C, Mahfoud Z, Ferron G, Querleu D, Rafii A.

Ann Surg Oncol. 2016 Feb;23(2):434-42. doi: 10.1245/s10434-015-4890-8. Epub 2015 Nov 5.

​

Epigenetics and Cardiovascular Disease in Diabetes.

Pasquier J, Hoarau-Véchot J, Fakhro K, Rafii A, Abi Khalil C.

Curr Diab Rep. 2015 Dec;15(12):108. doi: 10.1007/s11892-015-0677-3. Review.

​

Epithelial to Mesenchymal Transition in a Clinical Perspective.

Pasquier J, Abu-Kaoud N, Al Thani H, Rafii A.

J Oncol. 2015;2015:792182. doi: 10.1155/2015/792182. Epub 2015 Sep 6. Review.

​

SDF-1alpha concentration dependent modulation of RhoA and Rac1 modifies breast cancer and stromal cells interaction.

Pasquier J, Abu-Kaoud N, A